<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002087" GROUP_ID="STROKE" ID="063299111614493192" MERGED_FROM="" MODIFIED="2010-08-31 15:08:00 +0200" MODIFIED_BY="Hazel Fraser" REVIEW_NO="0007" REVMAN_SUB_VERSION="5.0.24" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2010-08-31 15:08:00 +0200" MODIFIED_BY="Hazel Fraser">
<TITLE>Tirilazad for acute ischaemic stroke</TITLE>
<CONTACT MODIFIED="2010-08-31 15:08:00 +0200" MODIFIED_BY="Hazel Fraser"><PERSON ID="7166" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Philip</FIRST_NAME><MIDDLE_INITIALS>MW</MIDDLE_INITIALS><LAST_NAME>Bath</LAST_NAME><SUFFIX>FRCP</SUFFIX><POSITION>Stroke Association Professor of Stroke Medicine</POSITION><EMAIL_1>philip.bath@nottingham.ac.uk</EMAIL_1><MOBILE_PHONE>07798 670726</MOBILE_PHONE><ADDRESS><DEPARTMENT>Division of Stroke Medicine</DEPARTMENT><ORGANISATION>University of Nottingham</ORGANISATION><ADDRESS_1>Nottingham City Hospital Campus</ADDRESS_1><ADDRESS_2>Hucknall Road</ADDRESS_2><CITY>Nottingham</CITY><ZIP>NG5 1PB</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 115 823 1768</PHONE_1><FAX_1>+44 115 823 1767</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2010-08-31 15:08:00 +0200" MODIFIED_BY="Hazel Fraser"><GROUP ID="D1513D3C82E26AA20046B372764B4E51"><GROUP_NAME>The Tirilazad International Steering Committee</GROUP_NAME><CONTACT_PERSON>Philip MW Bath</CONTACT_PERSON><ADDRESS><DEPARTMENT>Division of Stroke Medicine</DEPARTMENT><ORGANISATION>University of Nottingham</ORGANISATION><ADDRESS_1>South Block D Floor</ADDRESS_1><ADDRESS_2>Queens Medical Centre</ADDRESS_2><CITY>Nottingham</CITY><ZIP>NG7 2UH</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></GROUP></CREATORS>
<DATES MODIFIED="2010-08-31 14:02:28 +0100" MODIFIED_BY="Hazel Fraser">
<UP_TO_DATE>
<DATE DAY="23" MONTH="7" YEAR="2001"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="27" MONTH="7" YEAR="2010"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2001"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2001"/>
</DATES>
<WHATS_NEW MODIFIED="2010-08-31 14:01:52 +0100" MODIFIED_BY="Hazel Fraser">
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2010-08-31 14:01:52 +0100" MODIFIED_BY="Hazel Fraser">
<DATE DAY="30" MONTH="8" YEAR="2010"/>
<DESCRIPTION>
<P>The Cochrane Stroke Group Trials Register was last searched for this review on 27 July 2010. No new relevant trials were found. The Cochrane Stroke Group Editorial Board believes that it is very unlikely that there will be any further trials in this topic area.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2010-08-31 14:01:28 +0100" MODIFIED_BY="Hazel Fraser">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-08-31 14:01:28 +0100" MODIFIED_BY="Hazel Fraser">
<DATE DAY="6" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Wolfson Foundation</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>South Thames NHS Executive</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Trent NHS Executive</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Pharmacia &amp; Upjohn</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-10-06 10:11:22 +0100" MODIFIED_BY="Hazel Fraser">
<SUMMARY MODIFIED="2008-10-06 09:57:20 +0100" MODIFIED_BY="Hazel Fraser">
<TITLE MODIFIED="2008-10-06 09:57:20 +0100" MODIFIED_BY="Hazel Fraser">Tirilazad for acute ischaemic stroke</TITLE>
<SUMMARY_BODY MODIFIED="2008-10-06 09:57:11 +0100" MODIFIED_BY="Hazel Fraser">
<P>Tirilazad is not effective for acute ischaemic stroke. Tirilazad is a drug which in animal models of stroke protects brain tissue and reduces brain damage. However, when studied in man, tirilazad not only did not improve outcome after stroke, but appeared to marginally worsen it. It has no role in the clinical treatment of stroke.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-10-06 09:56:36 +0100" MODIFIED_BY="Hazel Fraser">
<ABS_BACKGROUND>
<P>Tirilazad mesylate is neuroprotective in experimental models of ischaemic stroke suggesting it might be of benefit clinically.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess whether tirilazad mesylate is safe and effective at improving outcome in patients with acute ischaemic stroke.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-10-06 09:55:53 +0100" MODIFIED_BY="Hazel Fraser">
<P>Trials of tirilazad were identified from searches of the Cochrane Stroke Group Trials Register (last searched: May 2001) and the Cochrane Controlled Trials Register (CENTRAL/CCTR). In addition, we contacted the Pharmacia &amp; Upjohn company, the manufacturer of tirilazad, to identify unpublished studies and further information.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Truly and quasi-randomised unconfounded placebo or open controlled trials of tirilazad administered within 24 hours onset of suspected or proven acute ischaemic stroke.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Data relating to early and end-of-trial case fatality, disability (Barthel Index and Glasgow Outcome Scale), phlebitis, and QTc were extracted by treatment group from published data and company reports.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-10-06 09:56:36 +0100" MODIFIED_BY="Hazel Fraser">
<P>Six trials (four published, two unpublished) assessing tirilazad in 1757 patients with presumed acute ischaemic stroke were identified; all were double-blind and placebo-controlled in design. Tirilazad did not alter early case fatality (odds ratio (OR) 1.11, 95% confidence intervals (CI) 0.79 to 1.56) or end-of-trial case fatality (OR 1.12, 95% CI 0.88 to 1.44). Tirilazad increased the odds of being dead or disabled by about one fifth, though the result was only just statistically significant; the odds ratios were similar whether the expanded Barthel Index or Glasgow Outcome Scale were used to assess outcome (OR 1.23, 95% CI 1.01 to 1.51; OR 1.23, 95% CI 1.01 to 1.50 respectively). Tirilazad significantly increased the rate of infusion site phlebitis (OR 2.81, 95% CI 2.14 to 3.69). Functional outcome (EBI) was significantly worse in prespecified subgroups of patients: females (OR 1.46, 95% CI 1.08 to 1.98) and subjects receiving low dose tirilazad (OR 1.31, 95% CI 1.03 to 1.67); a non-significant worse outcome was also seen in patients with mild-moderate stroke (OR 1.40, 95% CI 0.99 to 1.98).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Tirilazad mesylate increased the combined end-point of 'death or disability' by about one-fifth, but did not alter case fatality, when given to patients with acute ischaemic stroke. Although further trials of tirilazad are now not warranted, analysis of individual patient data from the trials may help elucidate why tirilazad appears to worsen outcome in acute ischaemic stroke.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-10-06 10:08:06 +0100" MODIFIED_BY="Hazel Fraser">
<BACKGROUND MODIFIED="2008-10-06 09:57:38 +0100" MODIFIED_BY="Hazel Fraser">
<P>Tirilazad mesylate (U-74006F, Freedox®, Pharmacia &amp; Upjohn) is a lipid soluble synthetic, non-glucocorticoid, 21-aminosteroid (or lazaroid) which has been developed for the acute treatment of subarachnoid haemorrhage (SAH), traumatic brain injury (TBI), spinal cord injury (SCI), and ischaemic stroke. Its proposed mechanism of action is to inhibit iron-dependent lipid peroxidation within membranes, effects that are mediated through (i) free radical scavenging of lipid peroxyl and hydroxyl groups, (ii) reducing the formation of hydroxyl radicals, (iii) decreasing membrane phospholipid fluidity, and (iv) maintaining endogenous antioxidant levels (especially vitamins E and C).</P>
<P>Tirilazad was neuroprotective in experimental models of TBI, SCI, and SAH (<LINK REF="REF-Hall-1988a" TYPE="REFERENCE">Hall 1988a</LINK>; <LINK REF="REF-Anderson-1988" TYPE="REFERENCE">Anderson 1988</LINK>; <LINK REF="REF-Zuccarello-1989" TYPE="REFERENCE">Zuccarello 1989</LINK>). While human studies have shown tirilazad to be ineffective in TBI (<LINK REF="REF-Marshall-1998" TYPE="REFERENCE">Marshall 1998</LINK>), it improved outcome in two of four phase III studies in SAH (<LINK REF="REF-Kassell-1996" TYPE="REFERENCE">Kassell 1996</LINK>; <LINK REF="REF-Clarke-1997" TYPE="REFERENCE">Clarke 1997</LINK>; <LINK REF="REF-Lazino-1999a" TYPE="REFERENCE">Lazino 1999a</LINK>; <LINK REF="REF-Lazino-1999b" TYPE="REFERENCE">Lazino 1999b</LINK>) and is licensed for this indication in some countries.</P>
<P>Tirilazad was also neuroprotective in animal models of ischaemic stroke. It improved outcome and reduced stroke lesion size, neuronal necrosis, brain injury, and cerebral oedema in gerbils and rats exposed to permanent focal ischaemia (<LINK REF="REF-Hall-1988b" TYPE="REFERENCE">Hall 1988b</LINK>; <LINK REF="REF-Young-1988" TYPE="REFERENCE">Young 1988</LINK>; <LINK REF="REF-Meden-1996" TYPE="REFERENCE">Meden 1996</LINK>). Tirilazad also blocked cortical hypoperfusion following spreading depression (<LINK REF="REF-Hall-1991" TYPE="REFERENCE">Hall 1991</LINK>). Bolus doses as low as 3 mg/kg appeared to be neuroprotective whilst doses as high as 60 mg/kg/day were well tolerated by monkeys. However, tirilazad had variable effects on neurological outcome in transient forebrain ischaemia in the rat (<LINK REF="REF-Lesiuk-1991" TYPE="REFERENCE">Lesiuk 1991</LINK>; <LINK REF="REF-Beck-1990" TYPE="REFERENCE">Beck 1990</LINK>).</P>
<P>Phase I results in normal healthy human volunteers found that single and multiple intravenous doses of up 12 mg/kg tirilazad were well tolerated (<LINK REF="REF-Fleishaker-1993a" TYPE="REFERENCE">Fleishaker 1993a</LINK>; <LINK REF="REF-Fleishaker-1993b" TYPE="REFERENCE">Fleishaker 1993b</LINK>; <LINK REF="REF-Fleishaker-1997" TYPE="REFERENCE">Fleishaker 1997</LINK>); local infusion-related irritation and thrombophlebitis were the main adverse events, partially explained by the presence of citrate in the vehicle solution (<LINK REF="REF-Fleishaker-1993b" TYPE="REFERENCE">Fleishaker 1993b</LINK>). Tirilazad did not alter cerebral blood flow or its reactivity to carbon dioxide, or cerebral oxygen metabolism in normal subjects (<LINK REF="REF-Olsen-1993" TYPE="REFERENCE">Olsen 1993</LINK>).</P>
<P>A number of phase II and III trials have been undertaken with tirilazad in patients with ischaemic stroke; this systematic review will assess these trials in the context of safety and efficacy. A version of this review has been published elsewhere (<LINK REF="REF-Bath-2000" TYPE="REFERENCE">Bath 2000</LINK>).</P>
</BACKGROUND>
<OBJECTIVES>
<P>To assess the safety and efficacy of tirilazad in acute ischaemic stroke.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-10-06 10:02:21 +0100" MODIFIED_BY="Hazel Fraser">
<SELECTION_CRITERIA MODIFIED="2008-10-06 09:58:50 +0100" MODIFIED_BY="Hazel Fraser">
<CRIT_STUDIES>
<P>Truly and quasi-randomised unconfounded placebo or open controlled trials of tirilazad administered within 24 hours of onset of suspected or proven acute ischaemic stroke. Trials involving patients with definite primary intracerebral haemorrhage (PICH) or SAH were excluded.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Adult patients with proven or suspected acute ischaemic stroke.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Tirilazad mesylate.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-10-06 09:58:50 +0100" MODIFIED_BY="Hazel Fraser">
<P>The incidence of the following outcomes, chosen a priori, was determined in each treatment group in each trial:<BR/>(1) early (about 10 days) case fatality;<BR/>(2) case fatality at the end of the trial;<BR/>(3) combined death or disability at the end of the trial, assessed as the extended Barthel Index (EBI, cut-off &lt; 60/100 equivalent to dead or disabled) and Glasgow Outcome Scale (GOS, comprising groups severely disabled, vegetative survival, dead) (<LINK REF="REF-Mahoney-1965" TYPE="REFERENCE">Mahoney 1965</LINK>; <LINK REF="REF-Jennett-1975" TYPE="REFERENCE">Jennett 1975</LINK>);<BR/>(4) phlebitis at the infusion site;<BR/>(5) QTc value and prolongation on the electrocardiogram at three days of treatment.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-10-06 10:00:49 +0100" MODIFIED_BY="Hazel Fraser">
<P>See: 'Specialized register' section in <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/STROKE/frame.html">Cochrane Stroke Group</A>
</P>
<P>Relevant trials were identified in the Cochrane Stroke Group Trials Register, which was last searched by the Review Group Co-ordinator in May 2001. We conducted a separate electronic search of <I>The Cochrane Library</I>, including the Cochrane Controlled Trials Register (CENTRAL/CCTR), using the text words: tirilazad, mesylate, Freedox, U74006F, U-74006F, lazaroid, aminosteroid, free radical scavenger, lipid peroxidation, antioxidant. A study of the publication quality of acute stroke randomised controlled trials was also searched (<LINK REF="REF-Bath-1998a" TYPE="REFERENCE">Bath 1998a</LINK>). The pharmaceutical company who make tirilazad (Freedox, a patented compound), Pharmacia &amp; Upjohn (formerly The Upjohn Company) was also contacted to identify trials and provide further information on each identified study.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-10-06 10:02:21 +0100" MODIFIED_BY="Hazel Fraser">
<P>Three of us (PB, RI, FB) independently selected trials for inclusion and extracted information from published data, internal company reports, and tabulated data provided by Pharmacia &amp; Upjohn (BM, SS-S).</P>
<P>Outcomes were analysed by tirilazad dose: low dose &lt;= 6 mg/kg/day, and high dose &gt; 6 mg/kg/day; this cut-off reflects dosing strategies in early and later trials.</P>
<P>To search for potential sources of heterogeneity in the trials and their results, end of trial case fatality and extended Barthel Index were assessed for the following pre-specified subgroups of subjects: treatment delay (within three hours, more than three hours); severity (mild-moderate stroke, National Institutes of Health Stroke Scale, NIHSS &lt; 16 or Unified Neurological Stroke Scale, UNSS &gt;= 16; severe stroke, NIHSS &gt;= 16 or UNSS &lt; 16); and gender.</P>
<P>The methodological quality of trials was assessed using published Cochrane Collaboration criteria. We analysed data for patients who received at least one dose of their allotted medication, tested for heterogeneity between trials, and calculated a weighted estimate of the treatment effect across trials by means of the Peto odds ratio (OR) for binary data and the weighted mean difference (WMD) for continuous data.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-10-06 10:06:10 +0100" MODIFIED_BY="Hazel Fraser">
<STUDY_DESCRIPTION MODIFIED="2008-10-06 10:03:03 +0100" MODIFIED_BY="Hazel Fraser">
<P>Six randomised controlled trials of tirilazad, involving 1757 patients with presumed or confirmed ischaemic stroke, were identified and have been included in the analyses (<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>); no studies were excluded. The first trial was a phase II sequential dose-escalation study involving 111 patients and tested tirilazad at doses ranging between 0.6 mg/kg/day and 6 mg/kg/day (<LINK REF="STD-STIPAS-P_x002f_20-1994" TYPE="STUDY">STIPAS P/20 1994</LINK>). The highest dose was well tolerated and was used in two phase III efficacy studies, one in North America (<LINK REF="STD-RANTTAS-I-P_x002f_35-1996" TYPE="STUDY">RANTTAS I P/35 1996</LINK>) and the other in Europe, Israel and New Zealand (<LINK REF="STD-TESS-I-P_x002f_37-1996" TYPE="STUDY">TESS I P/37 1996</LINK>). Both these trials were stopped prematurely after recruiting a total of 1110 patients to allow higher doses of tirilazad to be tested as a result of information from studies in patients with SAH, animal dose-response data, and interim analyses (<LINK REF="STD-RANTTAS-I-P_x002f_35-1996" TYPE="STUDY">RANTTAS I P/35 1996</LINK>; <LINK REF="STD-TESS-I-P_x002f_37-1996" TYPE="STUDY">TESS I P/37 1996</LINK>). A second phase II trial assessed the safety and feasibility of administering tirilazad at 10 mg/kg/day and involved 55 patients (<LINK REF="STD-M_x002f_57-1996" TYPE="STUDY">M/57 1996</LINK>). Two further phase III trials were then started, one in North America (<LINK REF="STD-RANTTAS-II-M_x002f_81-1997" TYPE="STUDY">RANTTAS II M/81 1997</LINK>) and the other in Europe and Australasia (<LINK REF="STD-TESS-II-M_x002f_88-1997" TYPE="STUDY">TESS II M/88 1997</LINK>). These studies differed from the previous trials since women were given a higher dose (12 mg/kg/day) than men (10 mg/kg/day) to compensate for differential pharmacokinetics. Following an alert from the safety monitoring committee of the Europe/Australasian study, both trials were stopped early having recruited a total of 481 patients. Subsequently, further development of tirilazad for ischaemic stroke was ceased.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-10-06 10:04:00 +0100" MODIFIED_BY="Hazel Fraser">
<P>All the trials were placebo-controlled and truly randomised using pre-numbered treatment and placebo vials thereby ensuring concealment of allocation. Patients were randomised in blocks of two (<LINK REF="STD-TESS-II-M_x002f_88-1997" TYPE="STUDY">TESS II M/88 1997</LINK>), four (<LINK REF="STD-RANTTAS-I-P_x002f_35-1996" TYPE="STUDY">RANTTAS I P/35 1996</LINK>; <LINK REF="STD-TESS-I-P_x002f_37-1996" TYPE="STUDY">TESS I P/37 1996</LINK>; <LINK REF="STD-RANTTAS-II-M_x002f_81-1997" TYPE="STUDY">RANTTAS II M/81 1997</LINK>) or five (<LINK REF="STD-M_x002f_57-1996" TYPE="STUDY">M/57 1996</LINK>). The trials were double-blind although the presence of injection site phlebitis may have reduced blinding in some instances.</P>
<P>Data on patients receiving at least one dose of tirilazad were analysed for all six studies; since all randomised patients received their allocated treatment in the two phase II safety trials (<LINK REF="STD-STIPAS-P_x002f_20-1994" TYPE="STUDY">STIPAS P/20 1994</LINK>; <LINK REF="STD-M_x002f_57-1996" TYPE="STUDY">M/57 1996</LINK>), their data is the same as intention to treat. In total, 1544 of 1591 (97.0%) of randomised patients in the four phase III studies received their medication so the exclusion of data from untreated patients is not likely to have materially affected the results. Where patients dropped out prior to the final outcome, missing data were replaced with the last observation carried forward.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-10-06 10:06:10 +0100" MODIFIED_BY="Hazel Fraser">
<SUBSECTION>
<HEADING LEVEL="3">Case fatality and disability</HEADING>
<P>Data on case-fatality were available for all six trials. Tirilazad had no effect on either early (OR 1.11, 95% CI 0.79 to 1.56) or end-of-trial (OR 1.12, 95% CI 0.88 to 1.44) case fatality; there was no evidence of heterogeneity between the trials nor of any dose relationship (&lt; 6 mg/kg/day versus &gt; 6 mg/kg/day) with mortality. Analysis of end-of-trial case fatality by gender revealed that males had a non-significant increase in mortality (OR 1.23, 95% CI 0.89 to 1.71) while females had a non-significant decrease (OR 0.89, 95% CI 0.60 to 1.31).</P>
<P>Three-month end-of-trial death or disability was assessed in five trials by using the EBI (cut off &lt;60/100). Patients who received tirilazad had a significantly worse outcome than those who received placebo (OR 1.23, 95% CI 1.01 to 1.51). Possible explanations for this finding were sought through analysis of functional outcome in pre-specified sub-groups of patients. Significant increases in combined death or disability were observed in females (OR 1.46, 95% CI 1.08 to 1.98) and those receiving low-dose tirilazad (OR 1.31, 95% CI 1.03 to 1.67); patients presenting with a milder stroke had a non-significantly worse outcome (OR 1.40, 95% CI 0.99 to 1.98). Functional outcome was not related to the time delay between stroke onset and drug administration. Alternative use of the GOS as a measure of functional outcome revealed virtually identical odds ratio as the EBI (OR 1.23, 95% CI 1.01 to 1.50).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Safety</HEADING>
<P>All six trials reported the incidence of phlebitis at the infusion site; tirilazad caused a two fold increase in phlebitis (OR 2.81, 95% CI, 2.14 to 3.69) raising the control rate from 10.5% to 23.7%. Tirilazad increased QTc non-significantly by 5.2 msec (95% CI -3.2 to 13.6 msec) when measured at the end of treatment on day four in four studies (N = 551).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-10-06 10:08:06 +0100" MODIFIED_BY="Hazel Fraser">
<P>This systematic review is the first to assess, in its entirety, data resulting from the commercial development of a potential neuroprotective agent in acute stroke. It also reports, for the first time, data from a phase II trial (<LINK REF="STD-M_x002f_57-1996" TYPE="STUDY">M/57 1996</LINK>) and two European-based phase III trials, TESS and TESS II (<LINK REF="STD-TESS-I-P_x002f_37-1996" TYPE="STUDY">TESS I P/37 1996</LINK>; <LINK REF="STD-TESS-II-M_x002f_88-1997" TYPE="STUDY">TESS II M/88 1997</LINK>). Our studies reinforce those of the individual studies and do not provide any evidence of benefit from tirilazad in acute ischaemic stroke. However, the aggregated data suggest that tirilazad may have worsened functional outcome after stroke as assessed with the expanded Barthel Index and Glasgow Outcome Scale. The risk difference for both measures was 5% giving a number needed to harm (NNH) of 20. Measures of functional outcome are most relevant to patients and have been used as the primary outcome in most recent efficacy trials in acute stroke. Furthermore, analysis of functional data by sub-groups found significantly worse outcomes with tirilazad in female patients and those given a low dose, and a trend to a worse outcome in those subjects with a mild-moderate stroke. It is difficult to rationalise these findings; treated-women had a trend to a lower death rate and yet a greater disability. Similarly, the relationship of a poor outcome with a low, rather than high, dose of a drug is counter-intuitive. The finding of a trend to a worse outcome in mild-moderate stroke could reflect that it is easier to detect worsening outcomes in patients with mild rather than severe stroke. However, each of these findings are likely to represent the play of chance. Since tirilazad caused phlebitis, blinding may have been partially compromised but this is unlikely to have contributed to a worse outcome.</P>
<P>It is not clear why tirilazad was not only ineffective but also potentially worsened outcome after stroke. The drug was neuroprotective in experimental stroke (<LINK REF="REF-Hall-1988b" TYPE="REFERENCE">Hall 1988b</LINK>; <LINK REF="REF-Young-1988" TYPE="REFERENCE">Young 1988</LINK>; <LINK REF="REF-Meden-1996" TYPE="REFERENCE">Meden 1996</LINK>; <LINK REF="REF-Lesiuk-1991" TYPE="REFERENCE">Lesiuk 1991</LINK>) although the relevance of such preclinical models to clinical efficacy has been questioned (<LINK REF="REF-del-Zoppo-1995" TYPE="REFERENCE">del Zoppo 1995</LINK>; <LINK REF="REF-Grotta-1995" TYPE="REFERENCE">Grotta 1995</LINK>), particularly since efficacy is usually judged differently in experimental (reduced infarct size) and human stroke (reduced death and dependency/disability). Tirilazad was not only safe and well tolerated in four trials studying patients with SAH (<LINK REF="REF-Kassell-1996" TYPE="REFERENCE">Kassell 1996</LINK>; <LINK REF="REF-Clarke-1997" TYPE="REFERENCE">Clarke 1997</LINK>; <LINK REF="REF-Lazino-1999a" TYPE="REFERENCE">Lazino 1999a</LINK>; <LINK REF="REF-Lazino-1999b" TYPE="REFERENCE">Lazino 1999b</LINK>), but also improved outcome in two of these studies; SAH is now a licensed indication for the drug in some countries. However, other studies provide indirect information on why tirilazad was not beneficial in acute ischaemic stroke. First, tirilazad was not always effective in experimental models of stroke (<LINK REF="REF-Beck-1990" TYPE="REFERENCE">Beck 1990</LINK>). Second, it was ineffective in closed TBI (<LINK REF="REF-Marshall-1998" TYPE="REFERENCE">Marshall 1998</LINK>), a condition known to involve cerebral ischaemia. Third, tirilazad had no effect on infarct volume (a weak surrogate marker of outcome (<LINK REF="REF-Saver-1999" TYPE="REFERENCE">Saver 1999</LINK>)) in two of the four phase III trials in ischaemic stroke (<LINK REF="REF-van-der-Worp-1999" TYPE="REFERENCE">van der Worp 1999</LINK>). Fourth, more than three-quarters of patients received tirilazad after three hours at a time when neuroprotection is less likely to be effective. Fifth, tirilazad caused thrombophlebitis and might then have induced fever and a systemic inflammatory state, clinical scenarios known to be associated with a poor outcome (<LINK REF="REF-Reith-1996" TYPE="REFERENCE">Reith 1996</LINK>). Lastly, tirilazad can prolong QTc interval which could increase the risk of fatal ventricular dysrhythmias. Analysis of four trials where ECGs were performed revealed that tirilazad non-significantly increased QTc by 5.2 msec, although this prolongation is unlikely to have caused any significant clinical effects. No satisfactory biochemical explanation for toxicity exists. In particular, although tirilazad is a steroid, it has not been found to exhibit glucocorticoid activity in man (<LINK REF="REF-Fleishaker-1993a" TYPE="REFERENCE">Fleishaker 1993a</LINK>; <LINK REF="REF-Fleishaker-1993b" TYPE="REFERENCE">Fleishaker 1993b</LINK>) or to affect the pituitary adrenocortical axis in rats (<LINK REF="REF-Burrin-1990" TYPE="REFERENCE">Burrin 1990</LINK>). Hence, it is unlikely that tirilazad worsened outcome through glucocorticoid effects although it remains unclear what effects corticosteroids have in acute ischaemic stroke (<LINK REF="REF-Qizilbash-1998" TYPE="REFERENCE">Qizilbash 1998</LINK>). We plan to perform a systematic review of the individual patient data from the six RCTs of tirilazad in ischaemic stroke to further explore why sub-groups of patients receiving the drug fared worse. This approach will allow multivariate analyses to be performed with assessment of interactions between prognostic variables (including age, gender, stroke severity, time-to-treatment), and the association between QTc and phlebitis with outcome.</P>
<P>Alternatively, the apparent negative effect of tirilazad on functional outcome may be a chance finding and incorrect, i.e. tirilazad might have no detrimental effect on outcome. Four points support this assertion: first, the increase in death or disability was modest (OR 1.23) and only just significant with a lower 95% CI of 1.01. Second, all four phase III trials were stopped prematurely making these trials grossly underpowered and their results very unstable. Three, it might be expected that a potentially toxic drug would increase early mortality, as seen with selfotel (<LINK REF="REF-Davis-1997" TYPE="REFERENCE">Davis 1997</LINK>; <LINK REF="REF-Davis-2000" TYPE="REFERENCE">Davis 2000</LINK>), an observation not seen with tirilazad. Last, lower doses tended to be associated with the worst outcome.</P>
<P>Tirilazad is not the only putative neuroprotectant to have failed development in stroke. Three other drugs have also been associated with a worse outcome - selfotel (CGS 19755, a glutamate receptor antagonist) (<LINK REF="REF-Davis-1997" TYPE="REFERENCE">Davis 1997</LINK>; <LINK REF="REF-Davis-2000" TYPE="REFERENCE">Davis 2000</LINK>), enlimomab (an anti-ICAM antibody) (<LINK REF="REF-Enlimomab-1997" TYPE="REFERENCE">Enlimomab 1997</LINK>), and diaspirin cross-linked haemoglobin (DCLHb, a human haemoglobin solution) (<LINK REF="REF-Saxena-1999" TYPE="REFERENCE">Saxena 1999</LINK>). Development of other potential neuroprotectants has also ceased, including aptiganel (NMDA ion channel blocker), calcium channel blockers (flunarizine, isradipine, lifarizine, nimodipine (<LINK REF="REF-Horn-2000" TYPE="REFERENCE">Horn 2000</LINK>)), eliprodil (NMDA polyamine receptor antagonist), lubeluzole (modulator of nitric oxide activity), and GV150526 (glycine receptor antagonist). Unfortunately, there is no common explanation for the failure of all of these latter drugs, but small sample sizes, unrealistic expectations for the magnitude of efficacy, administration too late after the onset of stroke (in contrast to SAH where drugs are generally administered prior to the development of ischaemia), inadequate phase II testing, and the failure of the drug to reach the ischaemic area because of arterial occlusion or poor brain penetration, have all contributed to varying degrees. In some cases, unintended collateral effects may have contributed to study failures, e.g. on blood pressure or infection (<LINK REF="REF-Enlimomab-1997" TYPE="REFERENCE">Enlimomab 1997</LINK>; <LINK REF="REF-Saxena-1999" TYPE="REFERENCE">Saxena 1999</LINK>; <LINK REF="REF-Wahlgren-1994" TYPE="REFERENCE">Wahlgren 1994</LINK>). Unfortunately, many trial results have not been published in full making a detailed analysis of study design, and drug safety and efficacy impossible, e.g. trials relating to aptiganel, eliprodil, and enlimomab. Other compounds have been incompletely tested, e.g. prostacyclin, pentoxifylline and theophylline (<LINK REF="REF-Bath-2000a" TYPE="REFERENCE">Bath 2000a</LINK>; <LINK REF="REF-Bath-2000b" TYPE="REFERENCE">Bath 2000b</LINK>; <LINK REF="REF-Mohiuddin-2000" TYPE="REFERENCE">Mohiuddin 2000</LINK>), and their safety and efficacy remains unclear. Only agents which alter haemostasis have shown promise. Aspirin was found to have small but useful effects on death and disability, and early recurrent stroke, in two mega-trials (<LINK REF="REF-Gubitz-2001" TYPE="REFERENCE">Gubitz 2001</LINK>). Thrombolysis with intravenous tissue plasminogen activator appears to improve outcome when given hyperacutely after stroke although only one of the five phase III trials was positive on its primary outcome (<LINK REF="REF-Wardlaw-2000" TYPE="REFERENCE">Wardlaw 2000</LINK>). Finally, intra-arterial urokinase and ancrod each improved outcome in their first phase III studies (<LINK REF="REF-Furlan-1999" TYPE="REFERENCE">Furlan 1999</LINK>; <LINK REF="REF-Sherman-2000" TYPE="REFERENCE">Sherman 2000</LINK>) although the results of larger second efficacy trials are awaited.</P>
<P>Development of drugs which aim to improve outcome after acute stroke is in a critical state. Some drugs have been frankly toxic whilst more have simply been ineffective. Conventional phase III efficacy studies have been unreliable for at least two drugs (alteplase and lubeluzole) with studies reporting varying efficacy. It is clear that future studies of neuroprotectants will need to utilise improved trial designs and, especially, larger sample sizes. The addition of neuroprotection to thrombolysis may also improve the latter's efficacy (<LINK REF="REF-Sacchetti-1997" TYPE="REFERENCE">Sacchetti 1997</LINK>), as already demonstrated with tirilazad in experimental stroke (<LINK REF="REF-Meden-1996" TYPE="REFERENCE">Meden 1996</LINK>). Phase II studies also need to be improved, in particular with the use of neuroimaging to demonstrate that a drug is reducing stroke lesion size, a surrogate measure of efficacy. Further, labelling studies of putative neuroprotective drugs should be performed to ensure they are actually reaching the ischaemic brain lesion.</P>
<P>However, it is also apparent that continuous and cumulative real-time tracking of drug efficacy and safety needs to take place during phase II and phase III development by using sequential meta-analytical techniques so that unnecessary and potentially unsafe trials can be prevented from starting. In this respect, it is possible that interpretation of sequential reviews of data from trials of calcium channel blockers, lubeluzole, selfotel, and tirilazad would have led to earlier cessation of their development. Systematic reviews of individual patient data from trials of these drugs may contribute further information on the failure of these drugs, and how to improve the design of future studies. Such systematic reviews may also guard against bias (<LINK REF="REF-Goldstein-1999" TYPE="REFERENCE">Goldstein 1999</LINK>) by reporting previously unpublished data from individual trials, as we have done here.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Tirilazad mesylate should not be used in the treatment of acute ischaemic stroke.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Tirilazad should not be studied further as a sole treatment in patients with acute ischaemic stroke. Whether it should be used in combination with other drugs, especially thrombolytics, would depend on the results of further work in experimental models of stroke.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>Tirilazad International Steering Committee (by alphabetical order): PMW Bath (University of Nottingham, Nottingham, UK), S Blecic (Erasme Hospital, Brussels, Belgium), J Bogousslavsky (CHUV, Lausanne, Switzerland), G Boysen (Hvidovre Hospital, Hvidovre, Denmark), S Davis (Royal Melbourne Hospital, Melbourne, Australia), E Diez-Tejedor (Hospital La Paz, Madrid, Spain), JM Ferro (Hospital St Maria, Lisbon, Portugal), J Gommans (Hawkes Bay Hospital, Hastings, New Zealand), W Hacke (Universitätsklinikum Heidelberg, Heidelberg, Germany), B Indredavik (Trondheims Sykehus, Trondheim, Norway), B Norrving (Universitetssjukhuset, Lund, Sweden), J-M Orgogozo (Chairman, Hopital Pellegrin, Bordeaux, France), EB Ringelstein (Universitat Münster, Münster, Germany), ML Sacchetti (Università La Sapienza, Rome, Italy).</P>
<P>Analysis and writing: PMW Bath, R Iddenden, FJ Bath, J-M Orgogozo.</P>
<P>Pharmacia &amp; Upjohn (Kalamazoo, USA): BC Musch, DM Brosse, SA Naberhuis-Stehouwer</P>
<P>Part of this work was presented at the 7th European Stroke Conference, Edinburgh 1998 (<LINK REF="REF-Bath-1998b" TYPE="REFERENCE">Bath 1998b</LINK>).</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>The members of the Tirilazad International Steering Committee were all members of one or more tirilazad trial Advisory Committees. As such, they received expenses and honoraria from Pharmacia &amp; Upjohn for attending meetings. Data extraction and analyses were performed independently of the company.<BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-10-06 10:11:22 +0100" MODIFIED_BY="Hazel Fraser">
<P>Analysis and writing: PMW Bath, R Iddenden, FJ Bath, J-M Orgogozo.</P>
<P>Tirilazad International Steering Committee: PMW Bath, S Blecic, J Bogousslavsky, G Boysen, S Davis, E Diez-Tejedor, JM Ferro, J Gommans, W Hacke, B Indredavik, B Norrving, J-M Orgogozo, EB Ringelstein, ML Sacchetti.</P>
<P>Pharmacia &amp; Upjohn (Kalamazoo, USA): BC Musch, DM Brosse, SA Naberhuis-Stehouwer.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-10-06 10:37:24 +0100" MODIFIED_BY="Hazel Fraser">
<STUDIES MODIFIED="2008-10-06 10:20:06 +0100" MODIFIED_BY="Hazel Fraser">
<INCLUDED_STUDIES MODIFIED="2008-10-06 10:20:06 +0100" MODIFIED_BY="Hazel Fraser">
<STUDY DATA_SOURCE="UNPUB" ID="STD-M_x002f_57-1996" MODIFIED="2008-10-06 10:20:06 +0100" MODIFIED_BY="Hazel Fraser" NAME="M/57 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-10-06 10:20:06 +0100" MODIFIED_BY="Hazel Fraser" NOTES="&lt;p&gt;* Peters GR, Eckert SM, Brosse DM, Naberhuis-Stehouwer SA, Musch BC. A pilot randomized, vehicle controlled, double blind European safety study of high dose tirilazad mesylate in patients with acute ischemic stroke (protocol M/2700/0057). :Peters GR, Eckert SM, Brosse DM, Naberhuis-Stehouwer SA, Musch BC. A pilot randomized, vehicle controlled, double blind European safety study of high dose tirilazad mesylate in patients with acute ischemic stroke (protocol M/2700/0057). Technical report 7217-95-010, Pharmacia &amp;amp; Upjohn, 1996.&lt;/p&gt;" NOTES_MODIFIED="2008-10-06 10:20:06 +0100" NOTES_MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Peters GR, Eckert SM, Brosse DM, Naberhuis-Stehouwer SA, Musch BC</AU>
<TI>A pilot randomized, vehicle controlled, double blind European safety study of high dose tirilazad mesylate in patients with acute ischemic stroke (protocol M/2700/0057)</TI>
<SO>Kalamazoo, Pharmacia &amp; Upjohn</SO>
<YR>1996, pp 1-40</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-RANTTAS-I-P_x002f_35-1996" NAME="RANTTAS I P/35 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ford G, Haley EC, Hwang LJ, for the RANTTAS Investigators</AU>
<TI>Correlations between outcome measures in an ischemic stroke trial</TI>
<SO>Stroke</SO>
<YR>1995</YR>
<VL>26</VL>
<NO>1</NO>
<PG>158 (abstract)</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnston KC, Connors AF, Wagner DP, Knaus WA, Wang X-Q, Haley EC, for the Randomized Trial of Tirilazad mesylate in Acute Stroke (RANTTAS) Investigators</AU>
<TI>A predictive risk model for outcomes of ischemic stroke</TI>
<SO>Stroke</SO>
<YR>2000</YR>
<VL>31</VL>
<PG>448-455</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnston KC, Knaus WA, Wagner DP, Haley EC, for the RANTTAS Investigatots</AU>
<TI>A predictive model for outcomes in acute ischemic stroke</TI>
<SO>Ann Neurol</SO>
<YR>1998</YR>
<VL>44</VL>
<NO>3</NO>
<PG>513 (abstract)</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Peters GR, Eckert SM, Naberhuis-Stehouwer SA, Musch BC. A United States/Canadian, multicenter, randomized, double-blind, vehicle controlled trial of the efficacy of tirilazad mesylate in patients with acute ischemic stroke (RANTTAS) (protocol P/2700/0035). :Peters GR, Eckert SM, Naberhuis-Stehouwer SA, Musch BC. A United States/Canadian, multicenter, randomized, double-blind, vehicle controlled trial of the efficacy of tirilazad mesylate in patients with acute ischemic stroke (RANTTAS) (protocol P/2700/0035). Technical report 7217-96-005, Pharmacia &amp;amp; Upjohn, 1996.&lt;/p&gt;" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Peters GR, Eckert SM, Naberhuis-Stehouwer SA, Musch BC</AU>
<TI>A United States/Canadian, multicenter, randomized, double-blind, vehicle controlled trial of the efficacy of tirilazad mesylate in patients with acute ischemic stroke (RANTTAS) (protocol P/2700/0035)</TI>
<SO>Kalamazoo, Pharmacia &amp; Upjohn</SO>
<YR>1996, pp 1-54</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saver JL, Johnston KC, Homer D, Wityk R, Koroshetz W, Truskowski LL, Haley EC, for the RANTTAS Invetsigators</AU>
<TI>Infarct volume as a surrogate or auxiliary measure in ischemic stroke clinical trials</TI>
<SO>Stroke</SO>
<YR>1999</YR>
<VL>30</VL>
<PG>293-298</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>The RANTTAS Investigators</AU>
<TI>A randomised trial of tirilazad mesylate in patients with acute stroke (RANTTAS)</TI>
<SO>Stroke</SO>
<YR>1996</YR>
<VL>27</VL>
<PG>1453-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The RANTTAS Investigators</AU>
<TI>Randomized trial of tirilazad in acute stroke (RANTTAS)</TI>
<SO>Stroke</SO>
<YR>1996</YR>
<VL>27</VL>
<PG>195 (Abstract)</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-RANTTAS-II-M_x002f_81-1997" NAME="RANTTAS II M/81 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Haley EC</AU>
<TI>High-dose tirilazad for acute stroke (RANTTAS II)</TI>
<SO>Stroke</SO>
<YR>1998</YR>
<VL>29</VL>
<PG>1256-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;* Musch BC, Fleishaker DL, Naberhuis-Stehouwer SA, Peters GR. A United States/Canadian, multicenter, randomized, double-blind, vehicle controlled trial pf the efficacy of high dose tirilazad mesylate in patients with acute ischemic stroke (RANTTAS II) (protocol M/2700/0081). :Musch BC, Fleishaker DL, Naberhuis-Stehouwer SA, Peters GR. A United States/Canadian, multicenter, randomized, double-blind, vehicle controlled trial pf the efficacy of high dose tirilazad mesylate in patients with acute ischemic stroke (RANTTAS II) (protocol M/2700/0081). Technical report 1021-97-002, Pharmacia &amp;amp; Upjohn, 1997.&lt;/p&gt;" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Musch BC, Fleishaker DL, Naberhuis-Stehouwer SA, Peters GR</AU>
<TI>A United States/Canadian, multicenter, randomized, double-blind, vehicle controlled trial of the efficacy of high dose tirilazad mesylate in patients with acute ischemic stroke (RANTTAS II) (protocol M/2700/0081)</TI>
<SO>Kalamazoo, Pharmacia &amp; Upjohn</SO>
<YR>1997, pp 1-56</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-STIPAS-P_x002f_20-1994" NAME="STIPAS P/20 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haley EC, Sheppard G, Burch G, Putman S, Adams R, Peters G, Hansen C, Torner J</AU>
<TI>Safety study of tirilazad mesylate in acute stroke (STIPAS)</TI>
<SO>Neurology</SO>
<YR>1994</YR>
<VL>43</VL>
<PG>A263 (Abstract)</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Peters GR, Naberhuis-Stehouwer SA, Bryan WJ. A phase II dose escalation study of the safety and tolerance of tirilazad mesylate (U-74006F) in patients with acute ischemic stroke (protocol P/2700/0020). :Peters GR, Naberhuis-Stehouwer SA, Bryan WJ. A phase II dose escalation study of the safety and tolerance of tirilazad mesylate (U-74006F) in patients with acute ischemic stroke (protocol P/2700/0020). Technical report 7217-93-028, Upjohn, 1993.&lt;/p&gt;" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Peters GR, Naberhuis-Stehouwer SA, Bryan WJ</AU>
<TI>A phase II dose escalation study of the safety and tolerance of tirilazad mesylate (U-74006F) in patients with acute ischemic stroke (protocol P/2700/0020)</TI>
<SO>Kalamazoo, The Upjohn Company</SO>
<YR>1993, pp 1-55</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>The STIPAS Investigators</AU>
<TI>Safety study of tirilazad mesylate in patients with acute ischemic stroke (STIPAS)</TI>
<SO>Stroke</SO>
<YR>1994</YR>
<VL>25</VL>
<PG>418-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-TESS-I-P_x002f_37-1996" NAME="TESS I P/37 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;* Peters GR, Eckert SM, Brosse DM, Naberhuis-Stehouwer SA, Musch BC. An international, multicenter, randomized, double-blind, vehicle controlled trial of the efficacy of tirilazad mesylate in patients with acute ischemic stroke (TESS). :Peters GR, Eckert SM, Brosse DM, Naberhuis-Stehouwer SA, Musch BC. An international, multicenter, randomized, double-blind, vehicle controlled trial of the efficacy of tirilazad mesylate in patients with acute ischemic stroke (TESS). Technical report 7217-96-001, Pharmacia &amp;amp; Upjohn, 1996.&lt;/p&gt;" PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>Peters GR, Eckert SM, Brosse DM, Naberhuis-Stehouwer SA, Musch BC</AU>
<TI>An international, multicenter, randomized, double-blind, vehicle controlled trial of the efficacy of tirilazad mesylate in patients with acute ischemic stroke (TESS) (protocol P/2700/0037)</TI>
<SO>Kalamazoo, Pharmacia &amp; Upjohn</SO>
<YR>1996, pp 1-52</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peters GR, Hwang L-J, Musch B, Brosse DM, Orgogozo JM</AU>
<TI>Safety and efficacy of 6 mg/kg/day tirilazad mesylate in acute ischemic stroke (TESS study)</TI>
<SO>Stroke</SO>
<YR>1996</YR>
<VL>27</VL>
<PG>195 (Abstract)</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van der Worp HB, Kappelle LJ, Algra A, Bar PR, Orgogozo J-M, Ringelstein EB, Bath PMW, van Gijn J</AU>
<TI>No effect of tirilazad mesylate on infarct volume of patients with acute ischaemic stroke</TI>
<SO>Cerebrovasc Dis</SO>
<YR>2000</YR>
<VL>10 (suppl 2)</VL>
<PG>107 (abstract)</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-TESS-II-M_x002f_88-1997" NAME="TESS II M/88 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;* Musch BC, Naberhuis-Stehouwer SA, Brosse D, Peters GR. An international, randomized, vehicle controlled trial of the efficacy of tirilazad mesylate in patients with acute ischemic stroke (TESS II) (protocol M/2700/0088). :Musch BC, Naberhuis-Stehouwer SA, Brosse D, Peters GR. An international, randomized, vehicle controlled trial of the efficacy of tirilazad mesylate in patients with acute ischemic stroke (TESS II) (protocol M/2700/0088). Technical report 7217-97-001, Pharmacia &amp;amp; Upjohn, 1997.&lt;/p&gt;" PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>Musch BC, Naberhuis-Stehouwer SA, Brosse D, Peters GR</AU>
<TI>An international, randomized, vehicle controlled trial of the efficacy of tirilazad mesylate in patients with acute ischemic stroke (TESS II) (protocol M/2700/0088)</TI>
<SO>Kalamazoo, Pharmacia &amp; Upjohn</SO>
<YR>1997, pp 1-56</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van der Worp HB, Kappelle LJ, Algra A, Bar PR, Orgogozo J-M, Ringelstein EB, Bath PMW, van Gijn J</AU>
<TI>No effect of tirilazad mesylate on infarct volume of patients with acute ischaemic stroke</TI>
<SO>Cerebrovasc Dis</SO>
<YR>2000</YR>
<VL>10 (suppl 2)</VL>
<PG>107 (abstract)</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES/>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-10-06 10:37:24 +0100" MODIFIED_BY="Hazel Fraser">
<ADDITIONAL_REFERENCES MODIFIED="2008-10-06 10:37:24 +0100" MODIFIED_BY="Hazel Fraser">
<REFERENCE ID="REF-Anderson-1988" NAME="Anderson 1988" TYPE="JOURNAL_ARTICLE">
<AU>Anderson DK, Braughler JM, Hall EK, Waters TR, McCall JM, Means ED</AU>
<TI>Effects of treatment with U-74006F on neurological outcome following experimental spinal cord injury</TI>
<SO>J Neurosurg</SO>
<YR>1988</YR>
<VL>69</VL>
<PG>562-567</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bath-1998a" NAME="Bath 1998a" TYPE="JOURNAL_ARTICLE">
<AU>Bath FJ, Owen VE, Bath PMW</AU>
<TI>Quality of full and final publications reporting acute stroke trials. A systematic review</TI>
<SO>Stroke</SO>
<YR>1998</YR>
<VL>29</VL>
<PG>2203-2210</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bath-1998b" NAME="Bath 1998b" TYPE="JOURNAL_ARTICLE">
<AU>Bath PM</AU>
<TI>Tirilazad in acute ischaemic stroke: a systematic review</TI>
<SO>Cerebrovasc Dis</SO>
<YR>1998</YR>
<VL>8</VL>
<NO>suppl 4</NO>
<PG>34 (Abstract)</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bath-2000a" MODIFIED="2008-10-06 10:27:30 +0100" MODIFIED_BY="Hazel Fraser" NAME="Bath 2000a" TYPE="COCHRANE_REVIEW">
<AU>Bath P, Bath F</AU>
<TI>Prostacyclin and analogues in acute ischaemic stroke</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-10-06 10:27:30 +0100" MODIFIED_BY="Hazel Fraser">
<IDENTIFIER MODIFIED="2008-10-06 10:27:30 +0100" MODIFIED_BY="Hazel Fraser" TYPE="DOI" VALUE="Art. No.: CD000177. DOI: 10.1002/14651858.CD000177"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bath-2000b" MODIFIED="2008-10-06 10:28:10 +0100" MODIFIED_BY="Hazel Fraser" NAME="Bath 2000b" TYPE="COCHRANE_REVIEW">
<AU>Bath PMW, Bath FJ, Asplund K</AU>
<TI>Pentoxifylline, propentofylline and pentifylline in acute ischaemic stroke</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-10-06 10:28:10 +0100" MODIFIED_BY="Hazel Fraser">
<IDENTIFIER MODIFIED="2008-10-06 10:28:10 +0100" MODIFIED_BY="Hazel Fraser" TYPE="DOI" VALUE="Art. No.: CD000162. DOI: 10.1002/14651858.CD000162"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Beck-1990" NAME="Beck 1990" TYPE="JOURNAL_ARTICLE">
<AU>Beck T, Bielenberg GW</AU>
<TI>Failure of the lipid peroxidation inhibitor U74006F to improve neurological outcome after transient forebrain ischemia in the rat</TI>
<SO>Brain Research</SO>
<YR>1990</YR>
<VL>532</VL>
<PG>336-338</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Burrin-1990" NAME="Burrin 1990" TYPE="JOURNAL_ARTICLE">
<AU>Burrin JM, Hart GR</AU>
<TI>Effects of a novel 21-amino stroid, U74006F, on the rat pituitary-adrenocortical axis</TI>
<SO>Journal of Endocrinology</SO>
<YR>1990</YR>
<VL>126</VL>
<PG>203-209</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clarke-1997" MODIFIED="2008-10-06 10:36:06 +0100" MODIFIED_BY="Hazel Fraser" NAME="Clarke 1997" TYPE="JOURNAL_ARTICLE">
<AU>Clarke HE, Kassell NFMD, Apperson-Hansen CM, Maile MHMS, Alves WM</AU>
<TI>A randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in North America</TI>
<SO>J Neurosurg</SO>
<YR>1997</YR>
<VL>86</VL>
<PG>466-475</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davis-1997" NAME="Davis 1997" TYPE="JOURNAL_ARTICLE">
<AU>Davis SM, Albers GW, Diener H-C, Lees KR, Norris J (ASSIST Steering Committee)</AU>
<TI>Termination of acute stroke studies involving selfotel treatment</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>349</VL>
<PG>32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davis-2000" NAME="Davis 2000" TYPE="JOURNAL_ARTICLE">
<AU>Davis SM, Lees KR, Albers GW, Diener HC, Markabi S, Karlsson G, Norris J, for the ASSIST Investigators</AU>
<TI>Selfotel in acute ischemic stroke. Possible neurotoxic effects of an NMDA antagonist</TI>
<SO>Stroke</SO>
<YR>2000</YR>
<VL>31</VL>
<PG>347-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-del-Zoppo-1995" NAME="del Zoppo 1995" TYPE="JOURNAL_ARTICLE">
<AU>del Zoppo GJ</AU>
<TI>Why do all drugs work in animals but none in stroke patients? 1 Drugs promoting cerebral blood flow</TI>
<SO>J Int Med</SO>
<YR>1995</YR>
<VL>237</VL>
<PG>79-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Enlimomab-1997" MODIFIED="2008-10-06 10:20:33 +0100" MODIFIED_BY="Hazel Fraser" NAME="Enlimomab 1997" TYPE="JOURNAL_ARTICLE">
<AU>The Enlimomab Acute Stroke Trial Investigators</AU>
<TI>The Enlimomab acute stroke trial: final results</TI>
<SO>Cerebrovasc Dis</SO>
<YR>1997</YR>
<VL>7</VL>
<NO>suppl 4</NO>
<PG>18 (Abstract)</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fleishaker-1993a" NAME="Fleishaker 1993a" TYPE="JOURNAL_ARTICLE">
<AU>Fleishaker JC, Peters GR, Cathcart BS</AU>
<TI>Evaluation of the pharmacokinetics and tolerability of tirilazad mesylate, 1 21-aminosteroid free radical scavenger. I. Single-dose administration</TI>
<SO>J Clin Pharmacol</SO>
<YR>1993</YR>
<VL>33</VL>
<PG>175-181</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fleishaker-1993b" NAME="Fleishaker 1993b" TYPE="JOURNAL_ARTICLE">
<AU>Fleishaker JC, Peters GR, Cathcart BS</AU>
<TI>Evaluation of the pharmacokinetics and tolerability of tirilazad mesylate, a 21-aminosteroid free radical scavenger: II. Multiple-dose administration</TI>
<SO>J Clin Pharmacol</SO>
<YR>1993</YR>
<VL>33</VL>
<PG>182-190</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fleishaker-1997" NAME="Fleishaker 1997" TYPE="JOURNAL_ARTICLE">
<AU>Fleishaker JC, Peters GR</AU>
<TI>Pharmacokinetics of tirilazad in healthy male subjects at doses above 6 mg/kg/day</TI>
<SO>Int J Clin Pharmacol Therapeutics</SO>
<YR>1997</YR>
<VL>35</VL>
<PG>28-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Furlan-1999" NAME="Furlan 1999" TYPE="JOURNAL_ARTICLE">
<AU>Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Callahan F, Clark WM, Silver F, Rivera F</AU>
<TI>Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized trial</TI>
<SO>J Am Med Assoc</SO>
<YR>1999</YR>
<VL>282</VL>
<PG>2003-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goldstein-1999" NAME="Goldstein 1999" TYPE="JOURNAL_ARTICLE">
<AU>Goldstein LB, Brott TG, Kothari RU, Smith WS</AU>
<TI>Clinical stroke trials. Guarding against bias</TI>
<SO>Stroke</SO>
<YR>1999</YR>
<VL>30</VL>
<PG>1165-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grotta-1995" NAME="Grotta 1995" TYPE="JOURNAL_ARTICLE">
<AU>Grotta J</AU>
<TI>Why do all drugs work in animals but none in stroke patients? 2 Neuroprotective therapy</TI>
<SO>J Int Med</SO>
<YR>1995</YR>
<VL>237</VL>
<PG>89-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gubitz-2001" MODIFIED="2008-10-06 10:29:01 +0100" MODIFIED_BY="Hazel Fraser" NAME="Gubitz 2001" TYPE="COCHRANE_REVIEW">
<AU>Gubitz G, Sandercock P, Counsell C</AU>
<TI>Antiplatelet therapy for acute ischaemic stroke</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-10-06 10:29:01 +0100" MODIFIED_BY="Hazel Fraser">
<IDENTIFIER MODIFIED="2008-10-06 10:29:01 +0100" MODIFIED_BY="Hazel Fraser" TYPE="DOI" VALUE="Art. No.: CD000029. DOI: 10.1002/14651858.CD000029"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hall-1988a" NAME="Hall 1988a" TYPE="JOURNAL_ARTICLE">
<AU>Hall ED, Yonkers PA, McCall JM, Braughler JM</AU>
<TI>Effects of the 21-aminosteroid U74006F on experimental head injury in mice</TI>
<SO>J Neurosurg</SO>
<YR>1988</YR>
<VL>68</VL>
<PG>456-461</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hall-1988b" NAME="Hall 1988b" TYPE="JOURNAL_ARTICLE">
<AU>Hall D, Kay E, Pazara E, Braughler JM</AU>
<TI>21-Aminosteroid peroxidation inhibitor U74006F protects against cerebral ischemia in gerbils</TI>
<SO>Stroke</SO>
<YR>1988</YR>
<VL>19, 8</VL>
<PG>997-1003</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hall-1991" NAME="Hall 1991" TYPE="JOURNAL_ARTICLE">
<AU>Hall E D, Smith SL</AU>
<TI>The 21-aminosteroid antioxidant tirilazad mesylate, U-74006F, blocks cortical hypoperfusion following spreading depression</TI>
<SO>Brain Research</SO>
<YR>1991</YR>
<VL>553</VL>
<PG>243-248</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Horn-2000" MODIFIED="2008-10-06 10:26:03 +0100" MODIFIED_BY="Hazel Fraser" NAME="Horn 2000" TYPE="COCHRANE_REVIEW">
<AU>Horn J, Limburg L, Orgogozo JM</AU>
<TI>Calcium antagonists for acute ischemic stroke</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-10-06 10:26:03 +0100" MODIFIED_BY="Hazel Fraser">
<IDENTIFIER MODIFIED="2008-10-06 10:26:03 +0100" MODIFIED_BY="Hazel Fraser" TYPE="DOI" VALUE="Art. No.: CD001928. DOI: 10.1002/14651858.CD001928"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jennett-1975" NAME="Jennett 1975" TYPE="JOURNAL_ARTICLE">
<AU>Jennett B, Bond M</AU>
<TI>Assessment of outcome after severe brain damage. A practical scale</TI>
<SO>Lancet</SO>
<YR>1975</YR>
<VL>i</VL>
<PG>480-484</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kassell-1996" MODIFIED="2008-10-06 10:36:49 +0100" MODIFIED_BY="Hazel Fraser" NAME="Kassell 1996" TYPE="JOURNAL_ARTICLE">
<AU>Kassell NF, Clarke HE Jr, Apperson-Hansen C, Alves WM</AU>
<TI>Randomised, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in Europe, Australia, and New Zealand</TI>
<SO>J Neurosurg</SO>
<YR>1996</YR>
<VL>8</VL>
<PG>220-229</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lazino-1999a" NAME="Lazino 1999a" TYPE="JOURNAL_ARTICLE">
<AU>Lanzino G, Kassell NF, Dorsch NWC, Pasqualin A, Brandt L, Schmiedek P, Truskowski LL, Alves WM</AU>
<TI>Double-blind, randomized, vehicle-controlled study of high-dose tirilazad mesylate in women with aneurysmal subarachnoid hemorrhage. Part 1. A cooperative study in Europe, Australia, New Zealand, and South Africa</TI>
<SO>J Neurosurg</SO>
<YR>1999</YR>
<VL>90</VL>
<PG>1011-1017</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lazino-1999b" NAME="Lazino 1999b" TYPE="JOURNAL_ARTICLE">
<AU>Lanzino G, Kassell NF</AU>
<TI>Double-blind, randomized, vehicle-controlled study of high-dose tirilazad mesylate in women with aneurysmal subarachnoid hemorrhage. Part II. A cooperative study in North America</TI>
<SO>J Neurosurg 1999;90:1018-1024</SO>
<YR>1999</YR>
<VL>90</VL>
<PG>1018-1024</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lesiuk-1991" NAME="Lesiuk 1991" TYPE="JOURNAL_ARTICLE">
<AU>Lesiuk H, Sutherland G, Peeling J, Butler K, Saunders J</AU>
<TI>Effect of U74006F on forebrain ischemia in rats</TI>
<SO>Stroke</SO>
<YR>1991</YR>
<VL>22</VL>
<PG>896-901</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mahoney-1965" MODIFIED="2008-10-06 10:30:41 +0100" MODIFIED_BY="Hazel Fraser" NAME="Mahoney 1965" TYPE="JOURNAL_ARTICLE">
<AU>Mahoney FI, Barthel DW</AU>
<TI>Functional evaluation: The Barthel index</TI>
<SO>Maryland State Med J</SO>
<YR>1965</YR>
<VL>14</VL>
<PG>61-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marshall-1998" NAME="Marshall 1998" TYPE="JOURNAL_ARTICLE">
<AU>Marshall LF, Maas AI, Marshall SB, Bricolo A, Fearnside M, Iannotti F, Klauber MR, Lagarrigue J, Lobato R, Persson L, Pickard JD, Piek J, Servadei F, Wellis GN, Morris GF, Means ED, Musch B</AU>
<TI>A multicenter trial on the efficacy of using tirilazad mesylate in cases of head injury</TI>
<SO>J Neurosurg</SO>
<YR>1998</YR>
<VL>89</VL>
<PG>519-525</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Meden-1996" NAME="Meden 1996" TYPE="JOURNAL_ARTICLE">
<AU>Meden P, Overgaard K, Pedersen H, Boysen G</AU>
<TI>Effect of early treatment with tirilazad (U74006F) combined with delayed thrombolytic therapy in rat embolic stroke</TI>
<SO>Cerebrovasc Dis</SO>
<YR>1996</YR>
<VL>6</VL>
<PG>141-148</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mohiuddin-2000" MODIFIED="2008-10-06 10:29:45 +0100" MODIFIED_BY="Hazel Fraser" NAME="Mohiuddin 2000" TYPE="COCHRANE_REVIEW">
<AU>Mohiuddin AA, Bath FJ, Bath PMW</AU>
<TI>Theophylline, aminophylline, caffeine and analogues, in acute ischaemic stroke</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-10-06 10:29:45 +0100" MODIFIED_BY="Hazel Fraser">
<IDENTIFIER MODIFIED="2008-10-06 10:29:45 +0100" MODIFIED_BY="Hazel Fraser" TYPE="DOI" VALUE="Art. No.: CD000211. DOI: 10.1002/14651858.CD000211"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Olsen-1993" NAME="Olsen 1993" TYPE="JOURNAL_ARTICLE">
<AU>Olsen KS, Videbaek C, Agerlin N, Kroll M, Boge-Rasmussen T, Paulson O, Gjerris F</AU>
<TI>The effect of tirilazad mesylate (U74006F) on cerebral oxygen consumption, and reactivity of cerebral blood flow to carbon dioxide in healthy volunteers</TI>
<SO>Anesthesiology</SO>
<YR>1993</YR>
<VL>79,4</VL>
<PG>666-671</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Qizilbash-1998" MODIFIED="2008-10-06 10:33:48 +0100" MODIFIED_BY="Hazel Fraser" NAME="Qizilbash 1998" TYPE="COCHRANE_REVIEW">
<AU>Qizilbash N, Lewington SL, Lopez-Arrieta JM</AU>
<TI>Corticosteroids following acute presumed ischaemic stroke</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-10-06 10:33:48 +0100" MODIFIED_BY="Hazel Fraser">
<IDENTIFIER MODIFIED="2008-10-06 10:33:48 +0100" MODIFIED_BY="Hazel Fraser" TYPE="DOI" VALUE="Art. No.: CD000064. DOI: 10.1002/14651858.CD000064"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Reith-1996" NAME="Reith 1996" TYPE="JOURNAL_ARTICLE">
<AU>Reith J, Jorgensen S, Pedersen P, Nakayama H, Raaschou H, Jeppesen L, Olsen T</AU>
<TI>Body temperature in acute stroke: relation to stroke severity, infarct size, mortality, and outcome</TI>
<SO>Lancet</SO>
<YR>1996</YR>
<VL>347</VL>
<PG>422-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sacchetti-1997" NAME="Sacchetti 1997" TYPE="JOURNAL_ARTICLE">
<AU>Sacchetti ML, Toni D, Fiorelli M, Argentino C, Fieschi C</AU>
<TI>The concept of combination therapy in acute ischemic stroke</TI>
<SO>Neurology</SO>
<YR>1997</YR>
<VL>49</VL>
<NO>suppl 4</NO>
<PG>S70-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Saver-1999" MODIFIED="2008-10-06 10:37:24 +0100" MODIFIED_BY="Hazel Fraser" NAME="Saver 1999" TYPE="JOURNAL_ARTICLE">
<AU>Saver JL, Johnston KC, Homer D, Wityk R, Koroshetz W, Truskowski LL, Haley EC, for the RANTTAS Investigators</AU>
<TI>Infarct volume as a surrogate or auxiliary outcome measure in ischemic stroke clinical trials</TI>
<SO>Stroke</SO>
<YR>1999</YR>
<VL>30</VL>
<PG>293-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Saxena-1999" NAME="Saxena 1999" TYPE="JOURNAL_ARTICLE">
<AU>Saxena R, Wijnhoud AD, Carton H, Hacke W, Kaste M, Przybelski RJ, Stern KN, Koudstaal PJ</AU>
<TI>Controlled safety study of a hemoglobin-based oxygen carrier, DCLHb, in acute ischemic stroke</TI>
<SO>Stroke</SO>
<YR>1999</YR>
<VL>30</VL>
<PG>993-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sherman-2000" NAME="Sherman 2000" TYPE="JOURNAL_ARTICLE">
<AU>Sherman DG, Atkinson RP, Chippendale T, Levin KA, Ng K, Futrell N, Hsu CY, Levy DE, The STAT Participants</AU>
<TI>Intravenous ancrod for treatment of acute ischemic stroke. The STAT study: a randomized controlled trial</TI>
<SO>J Am Med Assoc</SO>
<YR>2000</YR>
<VL>283</VL>
<PG>2395-402</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-der-Worp-1999" NAME="van der Worp 1999" TYPE="BOOK_SECTION">
<AU>van der Worp HB, Kappelle LJ, Algra A, Bar PR, Orgogozo JM, Ringelstein EB, Bath PMW, van Gijn J, TESS Investigators</AU>
<TI>The effect of tirilazad mesylate on infarct volume of patients with acute ischaemic stroke</TI>
<SO>Treatment of acute ischaemic stroke with antioxidants. The gap between laboratory and clinic</SO>
<YR>1999</YR>
<PG>83-94</PG>
<ED>van der Worp</ED>
<PB>Utrecht University PhD Thesis</PB>
<CY>Utrecht</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wahlgren-1994" NAME="Wahlgren 1994" TYPE="JOURNAL_ARTICLE">
<AU>Wahlgren NG, MacMahon DG, de Keyser J, Indredavik B, Ryman T, INWEST Study Group</AU>
<TI>Intravenous Nimodipine West European Stroke Trial (INWEST) of nimodipine in the treatment of acute ischaemic stroke</TI>
<SO>Cerebrovasc Dis</SO>
<YR>1994</YR>
<VL>4</VL>
<PG>204-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wardlaw-2000" MODIFIED="2008-10-06 10:26:51 +0100" MODIFIED_BY="Hazel Fraser" NAME="Wardlaw 2000" TYPE="COCHRANE_REVIEW">
<AU>Wardlaw JM, del Zoppo G, Yamaguchi T</AU>
<TI>Thrombolysis for acute ischaemic stroke</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-10-06 10:26:51 +0100" MODIFIED_BY="Hazel Fraser">
<IDENTIFIER MODIFIED="2008-10-06 10:26:51 +0100" MODIFIED_BY="Hazel Fraser" TYPE="DOI" VALUE="Art. No.: CD000213. DOI: 10.1002/14651858.CD000213."/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Young-1988" NAME="Young 1988" TYPE="JOURNAL_ARTICLE">
<AU>Young W, Wojak J, DeCrescito V</AU>
<TI>21-Aminosteroid reduces ion shifts and edema in the rat middle cerebral artery occlusion model of regional ischemia</TI>
<SO>Stroke</SO>
<YR>1988</YR>
<VL>19, 8</VL>
<PG>1013-1019</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zuccarello-1989" NAME="Zuccarello 1989" TYPE="JOURNAL_ARTICLE">
<AU>Zuccarello M, Marsch JT, Schmitt G, Woodward J, Anderson DK</AU>
<TI>Effect of the 21-aminosteroid U-74006F on cerebral vasospasm following subarachnoid hemorrhage</TI>
<SO>J Neurosurg</SO>
<YR>1989</YR>
<VL>71</VL>
<PG>98-104</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES>
<REFERENCE ID="REF-Bath-2000" NAME="Bath 2000" TYPE="JOURNAL_ARTICLE">
<AU>Bath PMW, Blecic S, Bogousslavsky J, Boysen G, Davis S, Diez-Tejedor E, Ferro JM, Gommans J, Hacke W, Indredavik B, Norrving B, Orgogozo JM, Ringelstein EB, Sacchetti ML, Iddenden R, Bath FJ, Musch BC, Brosse DM, Naberhuis-Stehouwer SA</AU>
<TI>Tirilazad mesylate in acute ischaemic stroke. A systematic review</TI>
<SO>Stroke</SO>
<YR>2000</YR>
<VL>32</VL>
<PG>2257-65</PG>
<IDENTIFIERS/>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-10-06 10:19:55 +0100" MODIFIED_BY="Hazel Fraser">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-10-06 10:19:55 +0100" MODIFIED_BY="Hazel Fraser" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-10-06 10:13:06 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-M_x002f_57-1996">
<CHAR_METHODS MODIFIED="2008-10-06 10:11:45 +0100" MODIFIED_BY="Hazel Fraser">
<P>Computer randomisation in blocks of 5 (3:2 ratio tirilazad:vehicle); sequential numbered identical vials; triple-blinded Intention-to-treat analysis (all patients dosed)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-06 10:13:06 +0100" MODIFIED_BY="Hazel Fraser">
<P>11 centres in Europe; 55 patients; mean age 71 years; male 47%; 100% CT pre-treatment; treatment within 24 hours (mean 13 hours)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-06 10:12:14 +0100" MODIFIED_BY="Hazel Fraser">
<P>Tirilazad mesylate (Upjohn, USA): 15 mg/kg on day 1, then 10 mg/kg/day<BR/>Placebo: matching vehicle<BR/>Treatment for 4 days (22 doses)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-06 10:12:25 +0100" MODIFIED_BY="Hazel Fraser">
<P>Primary efficacy: neurological impairment (Unified Neurological Stroke Scale) at 14 days<BR/>Other outcomes: pharmacokinetics<BR/>Safety endpoint: case-fatality at 14 days</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-06 10:12:34 +0100" MODIFIED_BY="Hazel Fraser">
<P>Refs: 28<BR/>Only 55 of planned 70 patients enrolled for 'administrative reasons'</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-06 10:14:16 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-RANTTAS-I-P_x002f_35-1996">
<CHAR_METHODS MODIFIED="2008-10-06 10:12:44 +0100" MODIFIED_BY="Hazel Fraser">
<P>Computer randomisation; sequential numbered identical vials; triple-blinded<BR/>Excluded from analysis: 19 tirilazad and 11 vehicle undosed patients</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-06 10:12:54 +0100" MODIFIED_BY="Hazel Fraser">
<P>27 centres in North America; 660 patients; mean age 69 years; male 55.2%; presumed ischaemic stroke; 100% CT by second dose; treatment within 6 hours (mean 4.2 hours)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-06 10:13:28 +0100" MODIFIED_BY="Hazel Fraser">
<P>Tirilazad mesylate (Upjohn, USA): 150 mg over 10 to 30 minutes, then 1.5 mg/kg every 6 hours (6 mg/kg/day)<BR/>Placebo: matching vehicle<BR/>Treatment for 3 days (12 doses)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-06 10:13:57 +0100" MODIFIED_BY="Hazel Fraser">
<P>Primary efficacy: expanded Barthel Index (favourable outcome &gt;=60) and Glasgow Outcome Scale (favourable outcome = 'good' or 'moderate') at 90 days<BR/>Other outcomes: neurological impairment (NIH Stroke Scale) at 90 days; stroke lesion volume (on CT) at 7 to 10 days<BR/>Safety endpoint: case fatality at 90 days</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-06 10:14:16 +0100" MODIFIED_BY="Hazel Fraser">
<P>Refs: 22, 23, 29<BR/>Trial stopped prematurely at 660 (556 fully eligible) patients of planned 1130 for reasons of 'futility'<BR/>Enrollment period 5/1993 to 12/1994</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-06 10:15:21 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-RANTTAS-II-M_x002f_81-1997">
<CHAR_METHODS MODIFIED="2008-10-06 10:14:29 +0100" MODIFIED_BY="Hazel Fraser">
<P>Computer randomisation in blocks of 4 stratified by gender; sequential numbered identical vials; triple-blinded<BR/>Excluded from analysis: 4 tirilazad and 3 vehicle undosed patients</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-06 10:14:44 +0100" MODIFIED_BY="Hazel Fraser">
<P>19 centres in North America; 126 patients; mean age 72; 57% male; treatment within 4 hours (mean 3.2 hours)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-06 10:14:58 +0100" MODIFIED_BY="Hazel Fraser">
<P>Tirilazad mesylate (Upjohn, USA): 300 mg, then male 10 mg/kg/day, female 12 mg/kg/day<BR/>Placebo: matching vehicle<BR/>Treatment for 3 days (12 doses)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-06 10:15:12 +0100" MODIFIED_BY="Hazel Fraser">
<P>Primary efficacy: age, gender and NIHSS adjusted expanded Barthel Index at 90 days<BR/>Other outcomes: Glasgow Outcome Scale; neurological impairment (NIH Stroke Scale); case fatality at 10 and 90 days</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-06 10:15:21 +0100" MODIFIED_BY="Hazel Fraser">
<P>Refs: 26, 31<BR/>Trial stopped prematurely at 126 patients of planned 890 following TESS II interim analysis<BR/>Enrollment period: 1/1996 to 11/1996</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-06 10:16:36 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-STIPAS-P_x002f_20-1994">
<CHAR_METHODS MODIFIED="2008-10-06 10:15:35 +0100" MODIFIED_BY="Hazel Fraser">
<P>Randomised, sequential, ascending dose, double-blind, placebo-controlled phase IIa trial<BR/>Computer randomisation in blocks of 4 (tirilazad:placebo 3:1)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-06 10:15:40 +0100" MODIFIED_BY="Hazel Fraser">
<P>5 centres in USA; 111 patients; mean age 66 years; male 56%; treatment within 12 hours</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-06 10:16:14 +0100" MODIFIED_BY="Hazel Fraser">
<P>Tirilazad mesylate (Upjohn, USA): 0.6 mg/kg/day (n = 28); 2 mg/kg/day (n = 26); 6 mg/kg/day (n = 30), all given in 4 divided doses over 3 days (12 doses)<BR/>Placebo: matching vehicle (n = 27)<BR/>Treatment for 3 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-06 10:16:31 +0100" MODIFIED_BY="Hazel Fraser">
<P>Primary efficacy: case fatality; medical events; vital signs<BR/>Other outcomes: Barthel Index at 90 days; Glasgow Outcome Scale at 90 days<BR/>Pharmacokinetic analyses</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-06 10:16:36 +0100" MODIFIED_BY="Hazel Fraser">
<P>Refs: 20, 21, 27<BR/>Enrollment period: 2/1991 to 6/1992</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-06 10:17:58 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-TESS-I-P_x002f_37-1996">
<CHAR_METHODS MODIFIED="2008-10-06 10:16:50 +0100" MODIFIED_BY="Hazel Fraser">
<P>Computer randomisation; sequential numbered identical vials; triple-blinded<BR/>Excluded from analysis: 4 vehicle undosed patients</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-06 10:16:59 +0100" MODIFIED_BY="Hazel Fraser">
<P>56 centres in Europe, New Zealand, Israel; 450 patients; mean age 71 years; male 55.8%; presumed ischaemic stroke; 100% CT by second dose; treatment within 6 hours (mean 4.4 hours)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-06 10:17:12 +0100" MODIFIED_BY="Hazel Fraser">
<P>Tirilazad mesylate (Upjohn, USA): 150 mg over 10 to 30 minutes, then 1.5 mg/kg every 6 hours (6 mg/kg/day)<BR/>Placebo: matching vehicle<BR/>Treatment for 3 days (12 doses)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-06 10:17:41 +0100" MODIFIED_BY="Hazel Fraser">
<P>Primary efficacy: expanded Barthel Index (favourable outcome &gt;= 60/100) and Glasgow Outcome scale (favourable outcome 'good' or 'moderate') at 90 days<BR/>Other outcomes: neurological impairment (Unified Neurological Stroke Scale) at 90 days<BR/>Safety endpoint: case fatality at 90 days</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-06 10:17:58 +0100" MODIFIED_BY="Hazel Fraser">
<P>Refs: 25, 30<BR/>Trial stopped prematurely at 450 of 1080 patients following 'futility' analysis<BR/>Conducted during 9/1993 to 1/1995</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-06 10:19:40 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-TESS-II-M_x002f_88-1997">
<CHAR_METHODS MODIFIED="2008-10-06 10:18:10 +0100" MODIFIED_BY="Hazel Fraser">
<P>Computer randomisation in blocks of 2 stratified by gender; sequential numbered identical vials; triple blinded<BR/>Excluded from analysis: 3 tirilazad and 3 vehicle undosed patients</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-06 10:18:16 +0100" MODIFIED_BY="Hazel Fraser">
<P>53 centres in Europe and Australasia; 355 patients; mean age 68; 59% male; treatment within 6 hours (mean 4.6 hours)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-06 10:18:30 +0100" MODIFIED_BY="Hazel Fraser">
<P>Tirilazad mesylate (Upjohn, USA): 300 mg, then male 10 mg/kg/day, female 12 mg/kg/day (12 doses)<BR/>Placebo: matching vehicle<BR/>Treatment for 3 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-06 10:18:51 +0100" MODIFIED_BY="Hazel Fraser">
<P>Primary efficacy: expanded Barthel Index at 3 months<BR/>Other outcomes: Glasgow Outcome Scale at 3 months; neurological impairment (UNSS) at 21 days and 3 months; case fatality at 10 and 90 days</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-06 10:19:40 +0100" MODIFIED_BY="Hazel Fraser">
<P>Refs: 32<BR/>Trial stopped at 355 of planned 910 patients following safety and 'futility' analysis<BR/>Enrollment period: 6/1995 to 11/1996</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>M/ and P/ are internal company codes<BR/>RANTTAS: Randomized Trial of Tirilazad in Acute Stroke<BR/>STIPAS: Study of Tirilazad mesylate In Patients with Acute ischemic Stroke<BR/>TESS: Tirilizad Efficacy Stroke Study</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-M_x002f_57-1996">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-RANTTAS-I-P_x002f_35-1996">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-RANTTAS-II-M_x002f_81-1997">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-STIPAS-P_x002f_20-1994">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-TESS-I-P_x002f_37-1996">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-TESS-II-M_x002f_88-1997">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Tirilazad in acute stroke</NAME>
<DICH_OUTCOME CHI2="5.207983861040277" CI_END="1.5587337150098268" CI_START="0.7886940248433738" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.1087668678988225" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="68" I2="3.9935580944510227" I2_Q="45.1154464171833" ID="CMP-001.01" LOG_CI_END="0.19277192918535438" LOG_CI_START="-0.10309144938239506" LOG_EFFECT_SIZE="0.0448402399014797" METHOD="PETO" NO="1" P_CHI2="0.39102889950417175" P_Q="0.17707481221939136" P_Z="0.5524495801964457" Q="1.8220062562612895" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="887" TOTAL_2="812" WEIGHT="100.0" Z="0.594093501470046">
<NAME>Case-fatality at 10 days, by dose</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.3376776509561434" CI_END="1.4227889318437914" CI_START="0.6030981864971687" DF="2" EFFECT_SIZE="0.9263268454294274" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="46" I2="14.445004888421142" ID="CMP-001.01.01" LOG_CI_END="0.15314047806430298" LOG_CI_START="-0.21961197744093025" LOG_EFFECT_SIZE="-0.033235749688313644" NO="1" P_CHI2="0.3107275887042653" P_Z="0.7267043830953819" STUDIES="3" TAU2="0.0" TOTAL_1="622" TOTAL_2="556" WEIGHT="63.00012316715748" Z="0.3495127741009261">
<NAME>Daily dose &lt;= 6 mg/kg/day</NAME>
<DICH_DATA CI_END="39.42500925829722" CI_START="0.38387264830984613" EFFECT_SIZE="3.890267691769136" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.595771803987673" LOG_CI_START="-0.4158128311263684" LOG_EFFECT_SIZE="0.5899794864306522" ORDER="1" O_E="0.9729729729729728" SE="1.1816147721705244" STUDY_ID="STD-STIPAS-P_x002f_20-1994" TOTAL_1="84" TOTAL_2="27" VAR="0.7162228567633975" WEIGHT="2.163245480953997"/>
<DICH_DATA CI_END="1.9998583611028822" CI_START="0.5797838706341343" EFFECT_SIZE="1.0767941406416852" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="21" LOG_CI_END="0.30099923807913015" LOG_CI_START="-0.23673387071960003" LOG_EFFECT_SIZE="0.03213268367976509" ORDER="2" O_E="0.7415730337078656" SE="0.31586708993019197" STUDY_ID="STD-RANTTAS-I-P_x002f_35-1996" TOTAL_1="308" TOTAL_2="315" VAR="10.022850244232535" WEIGHT="30.272540581984323"/>
<DICH_DATA CI_END="1.3350291976721658" CI_START="0.38934147465485247" EFFECT_SIZE="0.7209592474814132" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="25" LOG_CI_END="0.12549076401463313" LOG_CI_START="-0.4096693305373469" LOG_EFFECT_SIZE="-0.1420892832613569" ORDER="3" O_E="-3.3108108108108105" SE="0.314355688625025" STUDY_ID="STD-TESS-I-P_x002f_37-1996" TOTAL_1="230" TOTAL_2="214" VAR="10.119460333373457" WEIGHT="30.564337104219167"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0482999538228437" CI_END="2.6362084314131096" CI_START="0.8601665246100196" DF="2" EFFECT_SIZE="1.5058480151051916" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="22" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.4209797447057262" LOG_CI_START="-0.06541746303749302" LOG_EFFECT_SIZE="0.17778114083411653" NO="2" P_CHI2="0.5920585026506354" P_Z="0.1519271396752808" STUDIES="3" TAU2="0.0" TOTAL_1="265" TOTAL_2="256" WEIGHT="36.99987683284252" Z="1.4327575389752814">
<NAME>Daily dose &gt; 6 mg/kg/day</NAME>
<DICH_DATA CI_END="5.171052567637844" CI_START="0.38852341504167537" EFFECT_SIZE="1.4174184290246403" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.7135789527244969" LOG_CI_START="-0.4105828025594375" LOG_EFFECT_SIZE="0.15149807508252972" ORDER="1" O_E="0.7999999999999998" SE="0.6603381797442179" STUDY_ID="STD-M_x002f_57-1996" TOTAL_1="33" TOTAL_2="22" VAR="2.293333333333333" WEIGHT="6.926675018545754"/>
<DICH_DATA CI_END="2.8407849313251177" CI_START="0.3275402639797058" EFFECT_SIZE="0.9646094786574511" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.45343835562568113" LOG_CI_START="-0.4847353052924328" LOG_EFFECT_SIZE="-0.015648474833375833" ORDER="2" O_E="-0.11864406779660985" SE="0.5510878524578197" STUDY_ID="STD-RANTTAS-II-M_x002f_81-1997" TOTAL_1="56" TOTAL_2="62" VAR="3.2927467055591153" WEIGHT="9.94525567491068"/>
<DICH_DATA CI_END="4.093852768292027" CI_START="0.8967422435794224" EFFECT_SIZE="1.9160194978971434" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="10" LOG_CI_END="0.6121322195995386" LOG_CI_START="-0.04733237108938016" LOG_EFFECT_SIZE="0.28239992425507915" ORDER="3" O_E="4.333333333333334" SE="0.38737276497304235" STUDY_ID="STD-TESS-II-M_x002f_88-1997" TOTAL_1="176" TOTAL_2="172" VAR="6.66410502721742" WEIGHT="20.12794613938608"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.70493891528138" CI_END="1.4410797520782195" CI_START="0.8763930484696166" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.1238114953192417" ESTIMABLE="YES" EVENTS_1="166" EVENTS_2="142" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.15868801615685232" LOG_CI_START="-0.05730107591194802" LOG_EFFECT_SIZE="0.05069347012245214" METHOD="PETO" NO="2" P_CHI2="0.5926293851059814" P_Q="0.7251672228648391" P_Z="0.3575611889248852" Q="0.12359547485999656" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="900" TOTAL_2="820" WEIGHT="100.0" Z="0.9200221616720775">
<NAME>Case-fatality at end of trial, by dose</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.2821729765579963" CI_END="1.569334984722138" CI_START="0.8562847427362511" DF="2" EFFECT_SIZE="1.1592228446937174" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="93" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.19571565645385955" LOG_CI_START="-0.06738179415933074" LOG_EFFECT_SIZE="0.06416693114726439" NO="1" P_CHI2="0.5267198664719666" P_Z="0.3390557603918989" STUDIES="3" TAU2="0.0" TOTAL_1="637" TOTAL_2="567" WEIGHT="67.3954159536259" Z="0.9560326316654509">
<NAME>Daily dose &lt;= 6 mg/kg/day</NAME>
<DICH_DATA CI_END="10.587920743455605" CI_START="0.44540613010296354" EFFECT_SIZE="2.171618015254859" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.0248106817029115" LOG_CI_START="-0.3512438100869601" LOG_EFFECT_SIZE="0.3367834358079757" ORDER="1" O_E="1.1869158878504669" SE="0.8083012200569607" STUDY_ID="STD-STIPAS-P_x002f_20-1994" TOTAL_1="81" TOTAL_2="26" VAR="1.5305711794883627" WEIGHT="2.4637258094372614"/>
<DICH_DATA CI_END="1.9183820965248883" CI_START="0.8387143601808058" EFFECT_SIZE="1.2684536304765675" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="48" LOG_CI_END="0.2829351126809984" LOG_CI_START="-0.07638592107710059" LOG_EFFECT_SIZE="0.10327459580194889" ORDER="2" O_E="5.337878787878786" SE="0.21106695389731045" STUDY_ID="STD-RANTTAS-I-P_x002f_35-1996" TOTAL_1="331" TOTAL_2="329" VAR="22.447062461419264" WEIGHT="36.13252874050307"/>
<DICH_DATA CI_END="1.5596168010449603" CI_START="0.6173623424408972" EFFECT_SIZE="0.9812485320260588" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="44" LOG_CI_END="0.19301790499877375" LOG_CI_START="-0.2094598649234101" LOG_EFFECT_SIZE="-0.008220979962318188" ORDER="3" O_E="-0.3386727688787161" SE="0.23641743434938328" STUDY_ID="STD-TESS-I-P_x002f_37-1996" TOTAL_1="225" TOTAL_2="212" VAR="17.891263008679875" WEIGHT="28.799161403685574"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.299170463863387" CI_END="1.6291985230567356" CI_START="0.6818866784096042" DF="2" EFFECT_SIZE="1.054006057552323" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="49" I2="13.012104520544293" ID="CMP-001.02.02" LOG_CI_END="0.21197400770625044" LOG_CI_START="-0.16628779401014382" LOG_EFFECT_SIZE="0.02284310684805337" NO="2" P_CHI2="0.3167685199522987" P_Z="0.812871557603782" STUDIES="3" TAU2="0.0" TOTAL_1="263" TOTAL_2="253" WEIGHT="32.60458404637411" Z="0.23672317169764248">
<NAME>Daily dose &gt; 6 mg/kg/day</NAME>
<DICH_DATA CI_END="3.8213291633092044" CI_START="0.3085833956927816" EFFECT_SIZE="1.0859091717421905" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.5822144487461809" LOG_CI_START="-0.5106274462346558" LOG_EFFECT_SIZE="0.03579350125576254" ORDER="1" O_E="0.20000000000000018" SE="0.6419407387663694" STUDY_ID="STD-M_x002f_57-1996" TOTAL_1="33" TOTAL_2="22" VAR="2.4266666666666667" WEIGHT="3.906150447420738"/>
<DICH_DATA CI_END="1.4129929428101122" CI_START="0.2754612055400864" EFFECT_SIZE="0.6238787858599681" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="19" LOG_CI_END="0.15013999277121975" LOG_CI_START="-0.5599395561814124" LOG_EFFECT_SIZE="-0.20489978170509626" ORDER="2" O_E="-2.711864406779661" SE="0.41710424200523183" STUDY_ID="STD-RANTTAS-II-M_x002f_81-1997" TOTAL_1="56" TOTAL_2="62" VAR="5.7479209481507665" WEIGHT="9.252298344790445"/>
<DICH_DATA CI_END="2.3631852254914723" CI_START="0.7650711711383695" EFFECT_SIZE="1.344620722762985" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="25" LOG_CI_END="0.3734977627903251" LOG_CI_START="-0.11629816250004714" LOG_EFFECT_SIZE="0.12859980014513891" ORDER="3" O_E="3.5772594752186606" SE="0.2877085510444971" STUDY_ID="STD-TESS-II-M_x002f_88-1997" TOTAL_1="174" TOTAL_2="169" VAR="12.080765667366489" WEIGHT="19.446135254162925"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.901562198558883" CI_END="1.359847276927619" CI_START="0.8128804000348337" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.0513768108795258" ESTIMABLE="YES" EVENTS_1="148" EVENTS_2="139" I2="0.0" I2_Q="64.2222042354841" ID="CMP-001.03" LOG_CI_END="0.13349013593492184" LOG_CI_START="-0.0899733479186405" LOG_EFFECT_SIZE="0.021758394008140634" METHOD="PETO" NO="3" P_CHI2="0.44641024404545593" P_Q="0.09455711277240586" P_Z="0.702699419008617" Q="2.795029650741623" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="789" TOTAL_2="771" WEIGHT="100.00000000000001" Z="0.38167908136019074">
<NAME>Case-fatality at end of trial, by gender</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.256841285037379" CI_END="1.7795454484651667" CI_START="0.9041692313159359" DF="4" EFFECT_SIZE="1.268467674097579" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="75" I2="23.908678555975126" ID="CMP-001.03.01" LOG_CI_END="0.25030908408787395" LOG_CI_START="-0.04375027599788281" LOG_EFFECT_SIZE="0.10327940404499558" NO="1" P_CHI2="0.2619444876674609" P_Z="0.16858787089846866" STUDIES="5" TAU2="0.0" TOTAL_1="445" TOTAL_2="445" WEIGHT="57.74882003870212" Z="1.3767554429413071">
<NAME>Male</NAME>
<DICH_DATA CI_END="12.697388854885274" CI_START="0.08907689206211344" EFFECT_SIZE="1.063505494342788" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.1037144199710998" LOG_CI_START="-1.0502349441281305" LOG_EFFECT_SIZE="0.026739737921484708" ORDER="19295" O_E="0.03846153846153855" SE="1.265240518693198" STUDY_ID="STD-M_x002f_57-1996" TOTAL_1="17" TOTAL_2="9" VAR="0.6246745562130178" WEIGHT="1.0763218367465297"/>
<DICH_DATA CI_END="2.350889670128718" CI_START="0.7273075139437307" EFFECT_SIZE="1.3076007500522913" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="25" LOG_CI_END="0.37123224767932606" LOG_CI_START="-0.13828192563158673" LOG_EFFECT_SIZE="0.11647516102386962" ORDER="19293" O_E="2.994065281899111" SE="0.29929114753866454" STUDY_ID="STD-RANTTAS-I-P_x002f_35-1996" TOTAL_1="159" TOTAL_2="178" VAR="11.16380538954921" WEIGHT="19.235372086874204"/>
<DICH_DATA CI_END="1.3454381708308847" CI_START="0.14487228801627386" EFFECT_SIZE="0.4414937215778958" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="0.12886374469810333" LOG_CI_START="-0.8390146808684946" LOG_EFFECT_SIZE="-0.3550754680851957" ORDER="19296" O_E="-2.5294117647058822" SE="0.5685365782532956" STUDY_ID="STD-RANTTAS-II-M_x002f_81-1997" TOTAL_1="32" TOTAL_2="36" VAR="3.0937354748747614" WEIGHT="5.330543745709405"/>
<DICH_DATA CI_END="2.165074197357574" CI_START="0.6690610820424978" EFFECT_SIZE="1.203564242234851" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="26" LOG_CI_END="0.3354727842694342" LOG_CI_START="-0.17453423143540142" LOG_EFFECT_SIZE="0.0804692764170164" ORDER="19294" O_E="2.06451612903226" SE="0.29958064560046405" STUDY_ID="STD-TESS-I-P_x002f_37-1996" TOTAL_1="128" TOTAL_2="120" VAR="11.142239654206353" WEIGHT="19.198214063317536"/>
<DICH_DATA CI_END="4.209082517548716" CI_START="1.005114083527955" EFFECT_SIZE="2.0568442131380578" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="12" LOG_CI_END="0.6241874400185807" LOG_CI_START="0.002215358308505538" LOG_EFFECT_SIZE="0.31320139916354317" ORDER="19297" O_E="5.402843601895736" SE="0.36534947960795716" STUDY_ID="STD-TESS-II-M_x002f_88-1997" TOTAL_1="109" TOTAL_2="102" VAR="7.491745468430629" WEIGHT="12.908368306054445"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8496912627798815" CI_END="1.2084487691316812" CI_START="0.547574315739873" DF="4" EFFECT_SIZE="0.8134589773700776" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="64" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.08222824369275948" LOG_CI_START="-0.2615569308704899" LOG_EFFECT_SIZE="-0.08966434358886516" NO="2" P_CHI2="0.9316648490418907" P_Z="0.30660291142826235" STUDIES="5" TAU2="0.0" TOTAL_1="344" TOTAL_2="326" WEIGHT="42.25117996129789" Z="1.0223761647363785">
<NAME>Female</NAME>
<DICH_DATA CI_END="6.05312195675732" CI_START="0.2936782434055536" EFFECT_SIZE="1.3332929998241487" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7819794240551535" LOG_CI_START="-0.5321282261666838" LOG_EFFECT_SIZE="0.12492559894423491" ORDER="19300" O_E="0.4827586206896548" SE="0.7719133386780862" STUDY_ID="STD-M_x002f_57-1996" TOTAL_1="16" TOTAL_2="13" VAR="1.6782741634109055" WEIGHT="2.891686738575423"/>
<DICH_DATA CI_END="1.7077865356696322" CI_START="0.4581483902111283" EFFECT_SIZE="0.884544884186937" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="21" LOG_CI_END="0.2324335852204187" LOG_CI_START="-0.3389938350700528" LOG_EFFECT_SIZE="-0.05328012492481703" ORDER="19298" O_E="-1.0888888888888886" SE="0.3356592952899727" STUDY_ID="STD-RANTTAS-I-P_x002f_35-1996" TOTAL_1="142" TOTAL_2="128" VAR="8.875700582862912" WEIGHT="15.292939753578796"/>
<DICH_DATA CI_END="3.0763094512815066" CI_START="0.2799054817433786" EFFECT_SIZE="0.9279417432967756" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.48803001975889226" LOG_CI_START="-0.552988596111943" LOG_EFFECT_SIZE="-0.03247928817652527" ORDER="19301" O_E="-0.20000000000000018" SE="0.6114994880877856" STUDY_ID="STD-RANTTAS-II-M_x002f_81-1997" TOTAL_1="24" TOTAL_2="26" VAR="2.6742857142857144" WEIGHT="4.6078267209005"/>
<DICH_DATA CI_END="1.4852389475207548" CI_START="0.32578280187501607" EFFECT_SIZE="0.6956042738347799" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="18" LOG_CI_END="0.17179632923683613" LOG_CI_START="-0.487071845895902" LOG_EFFECT_SIZE="-0.15763775832953297" ORDER="19299" O_E="-2.423280423280424" SE="0.38702242752303734" STUDY_ID="STD-TESS-I-P_x002f_37-1996" TOTAL_1="97" TOTAL_2="92" VAR="6.676175347119848" WEIGHT="11.503131095359619"/>
<DICH_DATA CI_END="1.6737513119520881" CI_START="0.27003894191764577" EFFECT_SIZE="0.6722931156220576" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" LOG_CI_END="0.22369093043728963" LOG_CI_START="-0.5685736023578881" LOG_EFFECT_SIZE="-0.17244133596029926" ORDER="19302" O_E="-1.833333333333334" SE="0.4653801083365743" STUDY_ID="STD-TESS-II-M_x002f_88-1997" TOTAL_1="65" TOTAL_2="67" VAR="4.617260390161154" WEIGHT="7.955595652883559"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.960049618517272" CI_END="1.5007422632971816" CI_START="1.0066287361316821" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.2291014147588644" ESTIMABLE="YES" EVENTS_1="381" EVENTS_2="322" I2="32.88646477753467" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.1763061131366884" LOG_CI_START="0.002869324000011197" LOG_EFFECT_SIZE="0.08958771856834978" METHOD="PETO" NO="4" P_CHI2="0.20215183721157115" P_Q="0.6122757233550308" P_Z="0.042886369266188204" Q="0.25687436717276757" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="860" TOTAL_2="793" WEIGHT="100.0" Z="2.0248149510275226">
<NAME>Glasgow Outcome Scale, by dose</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.2481538035154394" CI_END="1.615699550773495" CI_START="1.0010591894122256" DF="2" EFFECT_SIZE="1.271774698062126" ESTIMABLE="YES" EVENTS_1="260" EVENTS_2="208" I2="38.426561025668704" ID="CMP-001.04.01" LOG_CI_END="0.20836060422785646" LOG_CI_START="4.597566752785886E-4" LOG_EFFECT_SIZE="0.10441018045156752" NO="1" P_CHI2="0.19709368605803856" P_Z="0.04899529587832989" STUDIES="3" TAU2="0.0" TOTAL_1="627" TOTAL_2="559" WEIGHT="69.59370051030609" Z="1.9686326026414787">
<NAME>Daily dose &lt;= 6 mg/kg/day</NAME>
<DICH_DATA CI_END="8.818705974936742" CI_START="1.1225711635691331" EFFECT_SIZE="3.146366956897877" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="2" LOG_CI_END="0.9454048630031983" LOG_CI_START="0.05021388193883547" LOG_EFFECT_SIZE="0.49780937247101686" ORDER="1" O_E="4.145454545454545" SE="0.5258396135440295" STUDY_ID="STD-STIPAS-P_x002f_20-1994" TOTAL_1="84" TOTAL_2="26" VAR="3.616541056941391" WEIGHT="3.7536264730422153"/>
<DICH_DATA CI_END="1.741387640647687" CI_START="0.9022500481650129" EFFECT_SIZE="1.2534620387743434" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="101" LOG_CI_END="0.24089545776587204" LOG_CI_START="-0.04467308608441669" LOG_EFFECT_SIZE="0.09811118584072767" ORDER="2" O_E="8.028571428571425" SE="0.16774437624474972" STUDY_ID="STD-RANTTAS-I-P_x002f_35-1996" TOTAL_1="312" TOTAL_2="318" VAR="35.53890658966289" WEIGHT="36.88601304328976"/>
<DICH_DATA CI_END="1.6695288379221735" CI_START="0.7948304526991276" EFFECT_SIZE="1.1519515450052271" ESTIMABLE="YES" EVENTS_1="121" EVENTS_2="105" LOG_CI_END="0.22259392506292836" LOG_CI_START="-0.09972550192227429" LOG_EFFECT_SIZE="0.061434211570327066" ORDER="3" O_E="3.9461883408071685" SE="0.18933202691800363" STUDY_ID="STD-TESS-I-P_x002f_37-1996" TOTAL_1="231" TOTAL_2="215" VAR="27.896635720662175" WEIGHT="28.954060993974114"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.4550214478290653" CI_END="1.6327745773158904" CI_START="0.7914038118335414" DF="1" EFFECT_SIZE="1.1367427256651765" ESTIMABLE="YES" EVENTS_1="121" EVENTS_2="114" I2="59.267158301843615" ID="CMP-001.04.02" LOG_CI_END="0.21292622969345107" LOG_CI_START="-0.10160186226523223" LOG_EFFECT_SIZE="0.0556621837141094" NO="2" P_CHI2="0.11714980564339195" P_Z="0.48786316479477376" STUDIES="2" TAU2="0.0" TOTAL_1="233" TOTAL_2="234" WEIGHT="30.406299489693914" Z="0.6937114882243164">
<NAME>Daily dose &gt; 6 mg/kg/day</NAME>
<DICH_DATA CI_END="1.4196326430864161" CI_START="0.3388416736061785" EFFECT_SIZE="0.6935637682934165" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="34" LOG_CI_END="0.15217597697402774" LOG_CI_START="-0.4700031818590449" LOG_EFFECT_SIZE="-0.15891360244250857" ORDER="2" O_E="-2.7394957983193287" SE="0.36547111773505403" STUDY_ID="STD-RANTTAS-II-M_x002f_81-1997" TOTAL_1="57" TOTAL_2="62" VAR="7.486759409646211" WEIGHT="7.770545909718772"/>
<DICH_DATA CI_END="2.0492385771860864" CI_START="0.8852251300432331" EFFECT_SIZE="1.346862088700682" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="80" LOG_CI_END="0.3115925229320738" LOG_CI_START="-0.0529462656844634" LOG_EFFECT_SIZE="0.12932312862380524" ORDER="3" O_E="6.494252873563212" SE="0.21413188892946014" STUDY_ID="STD-TESS-II-M_x002f_88-1997" TOTAL_1="176" TOTAL_2="172" VAR="21.809077904984044" WEIGHT="22.63575357997514"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.015693259836678" CI_END="1.5051109568493557" CI_START="1.007517344917151" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.2314322535367408" ESTIMABLE="YES" EVENTS_1="358" EVENTS_2="300" I2="33.50724800571702" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.17756851731933196" LOG_CI_START="0.003252531475148962" LOG_EFFECT_SIZE="0.0904105243972405" METHOD="PETO" NO="5" P_CHI2="0.19797948116673336" P_Q="0.3393154395964104" P_Z="0.04204189227488652" Q="0.913016541123989" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="858" TOTAL_2="793" WEIGHT="100.0" Z="2.0331052345407654">
<NAME>Expanded Barthel Index, by dose</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.8085505263146417" CI_END="1.6716084718105777" CI_START="1.0327841445760242" DF="2" EFFECT_SIZE="1.3139294979659002" ESTIMABLE="YES" EVENTS_1="249" EVENTS_2="194" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.22313456350728" LOG_CI_START="0.014009561969443082" LOG_EFFECT_SIZE="0.11857206273836154" NO="1" P_CHI2="0.40483522219014256" P_Z="0.026245134853678298" STUDIES="3" TAU2="0.0" TOTAL_1="625" TOTAL_2="559" WEIGHT="69.48043334902701" Z="2.2225651723212536">
<NAME>Daily dose &lt;= 6 mg/kg/day</NAME>
<DICH_DATA CI_END="6.880892653563766" CI_START="0.8993148267309613" EFFECT_SIZE="2.4875869400875303" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="3" LOG_CI_END="0.8376447826206175" LOG_CI_START="-0.0460882464460304" LOG_EFFECT_SIZE="0.39577826808729355" ORDER="1" O_E="3.3818181818181827" SE="0.5191091558227947" STUDY_ID="STD-STIPAS-P_x002f_20-1994" TOTAL_1="84" TOTAL_2="26" VAR="3.710928804306619" WEIGHT="3.890740441178427"/>
<DICH_DATA CI_END="1.8556529973736204" CI_START="0.955564277827111" EFFECT_SIZE="1.3316139516890912" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="95" LOG_CI_END="0.26849676745646595" LOG_CI_START="-0.0197400939917967" LOG_EFFECT_SIZE="0.12437833673233463" ORDER="2" O_E="9.990476190476187" SE="0.1693117592101847" STUDY_ID="STD-RANTTAS-I-P_x002f_35-1996" TOTAL_1="312" TOTAL_2="318" VAR="34.88395805168915" WEIGHT="36.5742469062105"/>
<DICH_DATA CI_END="1.7214217955832303" CI_START="0.8171030044487309" EFFECT_SIZE="1.1859927997650688" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="96" LOG_CI_END="0.23588729743387235" LOG_CI_START="-0.08772319261817936" LOG_EFFECT_SIZE="0.0740820524078465" ORDER="3" O_E="4.7207207207207205" SE="0.19009040375433603" STUDY_ID="STD-TESS-I-P_x002f_37-1996" TOTAL_1="229" TOTAL_2="215" VAR="27.67448920459719" WEIGHT="29.015446001638086"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.294126192398047" CI_END="1.5277983143098073" CI_START="0.7388064297544721" DF="1" EFFECT_SIZE="1.0624251587665503" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="106" I2="69.64293589274965" ID="CMP-001.05.02" LOG_CI_END="0.1840660265148363" LOG_CI_START="-0.13146933359625726" LOG_EFFECT_SIZE="0.026298346459289544" NO="2" P_CHI2="0.06952815818174041" P_Z="0.7438894748466556" STUDIES="2" TAU2="0.0" TOTAL_1="233" TOTAL_2="234" WEIGHT="30.519566650972987" Z="0.3267070409796003">
<NAME>Daily dose &gt; 6 mg/kg/day</NAME>
<DICH_DATA CI_END="1.227629148520477" CI_START="0.2923013379451062" EFFECT_SIZE="0.5990305857073969" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="33" LOG_CI_END="0.08906719166212378" LOG_CI_START="-0.5341691967505113" LOG_EFFECT_SIZE="-0.2225510025441938" ORDER="2" O_E="-3.8235294117647065" SE="0.3660921396234599" STUDY_ID="STD-RANTTAS-II-M_x002f_81-1997" TOTAL_1="57" TOTAL_2="62" VAR="7.461380564189784" WEIGHT="7.822918907639934"/>
<DICH_DATA CI_END="1.9725018469368494" CI_START="0.8494200679828534" EFFECT_SIZE="1.2944043622150703" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="73" LOG_CI_END="0.2950174185299277" LOG_CI_START="-0.07087748279523069" LOG_EFFECT_SIZE="0.11206996786734853" ORDER="3" O_E="5.5862068965517295" SE="0.2149284762473704" STUDY_ID="STD-TESS-II-M_x002f_88-1997" TOTAL_1="176" TOTAL_2="172" VAR="21.64771594129399" WEIGHT="22.696647743333052"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.176939760395943" CI_END="1.4378392320691544" CI_START="0.9486823992309285" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.1679266982082912" ESTIMABLE="YES" EVENTS_1="321" EVENTS_2="288" I2="14.393401380994801" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.15771032935111573" LOG_CI_START="-0.022879156748075915" LOG_EFFECT_SIZE="0.06741558630151988" METHOD="PETO" NO="6" P_CHI2="0.31725070753326323" P_Q="0.8469220333322209" P_Z="0.14337372595803263" Q="0.03726724337568221" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="756" TOTAL_2="751" WEIGHT="100.0" Z="1.4633423462432937">
<NAME>Expanded Barthel Index, by time</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.3276164524407275" CI_END="1.925261910050943" CI_START="0.768060912884335" DF="3" EFFECT_SIZE="1.2160256659195832" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="60" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="0.2844898187030108" LOG_CI_START="-0.1146043358532378" LOG_EFFECT_SIZE="0.08494274142488652" NO="1" P_CHI2="0.5072511260125623" P_Z="0.4041046552500025" STUDIES="4" TAU2="0.0" TOTAL_1="156" TOTAL_2="159" WEIGHT="20.475484670460872" Z="0.8343129662021228">
<NAME>Treatment &lt;= 3 hours</NAME>
<DICH_DATA CI_END="2.2471676438494677" CI_START="0.6001628947430163" EFFECT_SIZE="1.1613210745119285" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="24" LOG_CI_END="0.35163547299006986" LOG_CI_START="-0.22173085847213364" LOG_EFFECT_SIZE="0.06495230725896813" ORDER="2" O_E="1.3184713375796164" SE="0.33679822131001314" STUDY_ID="STD-RANTTAS-I-P_x002f_35-1996" TOTAL_1="82" TOTAL_2="75" VAR="8.815773459369549" WEIGHT="9.920202782144552"/>
<DICH_DATA CI_END="2.9963975986522033" CI_START="0.49881566640933883" EFFECT_SIZE="1.2225588186255258" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="19" LOG_CI_END="0.476599440350476" LOG_CI_START="-0.3020599150004693" LOG_EFFECT_SIZE="0.08726976267500337" ORDER="3" O_E="0.9605263157894726" SE="0.4573883597591176" STUDY_ID="STD-TESS-I-P_x002f_37-1996" TOTAL_1="39" TOTAL_2="37" VAR="4.780020775623269" WEIGHT="5.3788559353971666"/>
<DICH_DATA CI_END="2.386604854482894" CI_START="0.19060598964662823" EFFECT_SIZE="0.6744636240629729" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.3777805196672611" LOG_CI_START="-0.719863456113184" LOG_EFFECT_SIZE="-0.1710414682229614" ORDER="19315" O_E="-0.9473684210526319" SE="0.6447615047987427" STUDY_ID="STD-RANTTAS-II-M_x002f_81-1997" TOTAL_1="21" TOTAL_2="17" VAR="2.405480272516284" WEIGHT="2.7068359006489717"/>
<DICH_DATA CI_END="10.3592910709449" CI_START="0.7348036162264218" EFFECT_SIZE="2.7589933926112247" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="1.015330035861788" LOG_CI_START="-0.13382871504544028" LOG_EFFECT_SIZE="0.4407506604081739" ORDER="19316" O_E="2.2272727272727275" SE="0.6750215387104647" STUDY_ID="STD-TESS-II-M_x002f_88-1997" TOTAL_1="14" TOTAL_2="30" VAR="2.1946473188545066" WEIGHT="2.4695900522701852"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.812056064579533" CI_END="1.4593408733445763" CI_START="0.9154799923387174" DF="3" EFFECT_SIZE="1.1558535251272413" ESTIMABLE="YES" EVENTS_1="254" EVENTS_2="228" I2="48.38315448670691" ID="CMP-001.06.02" LOG_CI_END="0.16415674639768912" LOG_CI_START="-0.038351142691439105" LOG_EFFECT_SIZE="0.06290280185312506" NO="2" P_CHI2="0.12112105415943086" P_Z="0.223374447741021" STUDIES="4" TAU2="0.0" TOTAL_1="600" TOTAL_2="592" WEIGHT="79.52451532953913" Z="1.2176041803934163">
<NAME>Treatment &gt; 3 hours</NAME>
<DICH_DATA CI_END="2.043268172567066" CI_START="0.9484524811032349" EFFECT_SIZE="1.392100128521834" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="71" LOG_CI_END="0.31032537016786094" LOG_CI_START="-0.022984423037437605" LOG_EFFECT_SIZE="0.1436704735652117" ORDER="2" O_E="8.630021141649053" SE="0.19578782243887818" STUDY_ID="STD-RANTTAS-I-P_x002f_35-1996" TOTAL_1="230" TOTAL_2="243" VAR="26.08727087424397" WEIGHT="29.3554522808417"/>
<DICH_DATA CI_END="1.7779498415059516" CI_START="0.7829145496022918" EFFECT_SIZE="1.179823206831472" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="77" LOG_CI_END="0.24991950474192517" LOG_CI_START="-0.1062856359769588" LOG_EFFECT_SIZE="0.07181693438248325" ORDER="3" O_E="3.777173913043484" SE="0.20923666290215626" STUDY_ID="STD-TESS-I-P_x002f_37-1996" TOTAL_1="190" TOTAL_2="178" VAR="22.841489987406188" WEIGHT="25.703043932074713"/>
<DICH_DATA CI_END="1.0280219142288491" CI_START="0.16153197644699546" EFFECT_SIZE="0.40750265230573607" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="22" LOG_CI_END="0.012002372565117603" LOG_CI_START="-0.7917414930241851" LOG_EFFECT_SIZE="-0.38986956022953373" ORDER="19319" O_E="-4.027397260273972" SE="0.47212312524345706" STUDY_ID="STD-RANTTAS-II-M_x002f_81-1997" TOTAL_1="32" TOTAL_2="41" VAR="4.486311795000104" WEIGHT="5.0483514527051705"/>
<DICH_DATA CI_END="1.7849453782116678" CI_START="0.6947110286428575" EFFECT_SIZE="1.113562409462865" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="58" LOG_CI_END="0.2516249306419247" LOG_CI_START="-0.15819580658020457" LOG_EFFECT_SIZE="0.046714562030860024" ORDER="19320" O_E="1.8561151079136664" SE="0.2407307296896456" STUDY_ID="STD-TESS-II-M_x002f_88-1997" TOTAL_1="148" TOTAL_2="130" VAR="17.255872989061675" WEIGHT="19.417667663917552"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.644411030850302" CI_END="1.610274001160269" CI_START="1.008528367584123" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.274365336060786" ESTIMABLE="YES" EVENTS_1="313" EVENTS_2="282" I2="27.419103379059912" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.2068997810425315" LOG_CI_START="0.0036881184258124033" LOG_EFFECT_SIZE="0.10529394973417194" METHOD="PETO" NO="7" P_CHI2="0.20963574314765276" P_Q="0.4559232688126499" P_Z="0.042244107534586677" Q="0.5558846047637616" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="747" TOTAL_2="739" WEIGHT="100.0" Z="2.031107335194537">
<NAME>Expanded Barthel Index, by severity</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="8.767030209213328" CI_END="1.9815127844920581" CI_START="0.99393231809606" DF="3" EFFECT_SIZE="1.4033850488113266" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="68" I2="65.7808867038318" ID="CMP-001.07.01" LOG_CI_END="0.2969968786971797" LOG_CI_START="-0.0026431879147313635" LOG_EFFECT_SIZE="0.14717684539122414" NO="1" P_CHI2="0.03255429317799441" P_Z="0.05418115110051684" STUDIES="4" TAU2="0.0" TOTAL_1="419" TOTAL_2="400" WEIGHT="45.993608945310655" Z="1.9253854772274477">
<NAME>Impaiment mild</NAME>
<DICH_DATA CI_END="2.6479420651160814" CI_START="1.002217902567846" EFFECT_SIZE="1.62905338851181" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="32" LOG_CI_END="0.4229084788508788" LOG_CI_START="9.621562561733988E-4" LOG_EFFECT_SIZE="0.2119353175535261" ORDER="2" O_E="7.943820224719104" SE="0.2478533585601124" STUDY_ID="STD-RANTTAS-I-P_x002f_35-1996" TOTAL_1="220" TOTAL_2="225" VAR="16.27835005817584" WEIGHT="23.194384153740916"/>
<DICH_DATA CI_END="2.8721751461479657" CI_START="0.6542630987082227" EFFECT_SIZE="1.3708239169023535" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="14" LOG_CI_END="0.4582109197925145" LOG_CI_START="-0.1842475737858951" LOG_EFFECT_SIZE="0.13698167300330966" ORDER="3" O_E="2.214689265536723" SE="0.37738329934879095" STUDY_ID="STD-TESS-I-P_x002f_37-1996" TOTAL_1="95" TOTAL_2="82" VAR="7.021576726762019" WEIGHT="10.004769978741647"/>
<DICH_DATA CI_END="1.021260156301733" CI_START="0.14263067736245025" EFFECT_SIZE="0.3816582605638164" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="15" LOG_CI_END="0.009136388565065823" LOG_CI_START="-0.8457870552951231" LOG_EFFECT_SIZE="-0.41832533336502864" ORDER="19323" O_E="-3.8194444444444446" SE="0.5021862628627739" STUDY_ID="STD-RANTTAS-II-M_x002f_81-1997" TOTAL_1="37" TOTAL_2="35" VAR="3.965247891671013" WEIGHT="5.649926591794593"/>
<DICH_DATA CI_END="6.005506907820609" CI_START="1.043014098498106" EFFECT_SIZE="2.502764146595652" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="7" LOG_CI_END="0.7785496708526732" LOG_CI_START="0.018290178856586983" LOG_EFFECT_SIZE="0.3984199248546302" ORDER="19324" O_E="4.6" SE="0.44658018894368096" STUDY_ID="STD-TESS-II-M_x002f_88-1997" TOTAL_1="67" TOTAL_2="58" VAR="5.014193548387096" WEIGHT="7.1445282210335"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.3214962168732129" CI_END="1.6139309409459934" CI_START="0.8538179176006258" DF="3" EFFECT_SIZE="1.173883791160661" ESTIMABLE="YES" EVENTS_1="219" EVENTS_2="214" I2="0.0" ID="CMP-001.07.02" LOG_CI_END="0.20788494760554374" LOG_CI_START="-0.0686347356489243" LOG_EFFECT_SIZE="0.06962510597830968" NO="2" P_CHI2="0.9559362045343959" P_Z="0.32364181313515894" STUDIES="4" TAU2="0.0" TOTAL_1="328" TOTAL_2="339" WEIGHT="54.00639105468935" Z="0.9870017101942884">
<NAME>Impairment severe</NAME>
<DICH_DATA CI_END="2.1446578776986294" CI_START="0.5818779093874501" EFFECT_SIZE="1.1171074443519764" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="57" LOG_CI_END="0.33135802207873744" LOG_CI_START="-0.23516813019830896" LOG_EFFECT_SIZE="0.04809494594021421" ORDER="2" O_E="1.0" SE="0.3327802661972188" STUDY_ID="STD-RANTTAS-I-P_x002f_35-1996" TOTAL_1="84" TOTAL_2="84" VAR="9.029940119760479" WEIGHT="12.866408405918763"/>
<DICH_DATA CI_END="2.070924960232876" CI_START="0.7537107679232599" EFFECT_SIZE="1.2493512084632437" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="82" LOG_CI_END="0.31616436255969393" LOG_CI_START="-0.12279528011596665" LOG_EFFECT_SIZE="0.09668454122186362" ORDER="3" O_E="3.348484848484844" SE="0.2578470669929581" STUDY_ID="STD-TESS-I-P_x002f_37-1996" TOTAL_1="133" TOTAL_2="131" VAR="15.040961813084177" WEIGHT="21.431278052606025"/>
<DICH_DATA CI_END="3.3630905477441013" CI_START="0.20404207129410454" EFFECT_SIZE="0.8283791168971674" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" LOG_CI_END="0.5267385604030159" LOG_CI_START="-0.6902802764610125" LOG_EFFECT_SIZE="-0.08177085802899837" ORDER="19327" O_E="-0.36842105263157876" SE="0.7148828891143321" STUDY_ID="STD-RANTTAS-II-M_x002f_81-1997" TOTAL_1="16" TOTAL_2="22" VAR="1.956726809912405" WEIGHT="2.788063480072266"/>
<DICH_DATA CI_END="2.1070616985557757" CI_START="0.6755572430417996" EFFECT_SIZE="1.1930803795198845" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="59" LOG_CI_END="0.3236772527177362" LOG_CI_START="-0.17033784533345853" LOG_EFFECT_SIZE="0.0766697036921389" ORDER="19328" O_E="2.096446700507613" SE="0.2901869140094463" STUDY_ID="STD-TESS-II-M_x002f_88-1997" TOTAL_1="95" TOTAL_2="102" VAR="11.875293496511699" WEIGHT="16.920641116092295"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.600448137994517" CI_END="1.494128824682769" CI_START="0.9996790053177664" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.2221494251013147" ESTIMABLE="YES" EVENTS_1="358" EVENTS_2="300" I2="15.097929041868825" I2_Q="58.25661705839342" ID="CMP-001.08" LOG_CI_END="0.17438804422426732" LOG_CI_START="-1.3942859833102444E-4" LOG_EFFECT_SIZE="0.08712430781296816" METHOD="PETO" NO="8" P_CHI2="0.3040929630214636" P_Q="0.12167808079237419" P_Z="0.050367178133122824" Q="2.3955892635699083" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="858" TOTAL_2="793" WEIGHT="100.0" Z="1.956832385523302">
<NAME>Expanded Barthel Index, by gender</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.271123381572694" CI_END="1.388905056975038" CI_START="0.8122077873076501" DF="4" EFFECT_SIZE="1.0621108713811855" ESTIMABLE="YES" EVENTS_1="190" EVENTS_2="173" I2="24.114847814346568" ID="CMP-001.08.01" LOG_CI_END="0.14267255917093563" LOG_CI_START="-0.09033285088571552" LOG_EFFECT_SIZE="0.02616985414261003" NO="1" P_CHI2="0.26059245891226035" P_Z="0.6597457591248727" STUDIES="5" TAU2="0.0" TOTAL_1="488" TOTAL_2="457" WEIGHT="56.10422796028888" Z="0.44026421178556563">
<NAME>Male</NAME>
<DICH_DATA CI_END="1.989672502071773" CI_START="0.7933574578880684" EFFECT_SIZE="1.2563922628993918" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="50" LOG_CI_END="0.298781597893165" LOG_CI_START="-0.10053109135848343" LOG_EFFECT_SIZE="0.09912525326734078" ORDER="19329" O_E="4.1485714285714295" SE="0.23455825029610877" STUDY_ID="STD-RANTTAS-I-P_x002f_35-1996" TOTAL_1="166" TOTAL_2="184" VAR="18.17601085316648" WEIGHT="19.10299128622327"/>
<DICH_DATA CI_END="1.241708322789927" CI_START="0.18499640058755185" EFFECT_SIZE="0.47928234924284707" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="19" LOG_CI_END="0.0940195920728471" LOG_CI_START="-0.7328367214357516" LOG_EFFECT_SIZE="-0.3194085646814523" ORDER="19331" O_E="-3.117647058823529" SE="0.48569949155971387" STUDY_ID="STD-RANTTAS-II-M_x002f_81-1997" TOTAL_1="32" TOTAL_2="36" VAR="4.239012549708206" WEIGHT="4.455203094531583"/>
<DICH_DATA CI_END="7.994689565811096" CI_START="0.4896571592691733" EFFECT_SIZE="1.9785492114258774" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="2" LOG_CI_END="0.9028016047335691" LOG_CI_START="-0.3101078912990868" LOG_EFFECT_SIZE="0.29634685671724115" ORDER="19333" O_E="1.3442622950819665" SE="0.7124690419684186" STUDY_ID="STD-STIPAS-P_x002f_20-1994" TOTAL_1="49" TOTAL_2="12" VAR="1.970008062348831" WEIGHT="2.070478894013379"/>
<DICH_DATA CI_END="1.3908384350423675" CI_START="0.518233626509161" EFFECT_SIZE="0.8489871884076534" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="59" LOG_CI_END="0.14327668366219218" LOG_CI_START="-0.2854744104672008" LOG_EFFECT_SIZE="-0.07109886340250426" ORDER="19330" O_E="-2.5810276679841877" SE="0.2518505150437502" STUDY_ID="STD-TESS-I-P_x002f_37-1996" TOTAL_1="131" TOTAL_2="122" VAR="15.765738300194391" WEIGHT="16.5697943185934"/>
<DICH_DATA CI_END="2.219998126430276" CI_START="0.7556669599738735" EFFECT_SIZE="1.2952139728042087" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="43" LOG_CI_END="0.3463526079275143" LOG_CI_START="-0.12166956602453893" LOG_EFFECT_SIZE="0.1123415209514877" ORDER="19332" O_E="3.4225352112676077" SE="0.27491854172656116" STUDY_ID="STD-TESS-II-M_x002f_88-1997" TOTAL_1="110" TOTAL_2="103" VAR="13.230977681127959" WEIGHT="13.905760366927247"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.9337354928519153" CI_END="1.9803537102767679" CI_START="1.0797432974222658" DF="4" EFFECT_SIZE="1.46228370885976" ESTIMABLE="YES" EVENTS_1="168" EVENTS_2="127" I2="0.0" ID="CMP-001.08.02" LOG_CI_END="0.29674276637368624" LOG_CI_START="0.03332051681626292" LOG_EFFECT_SIZE="0.16503164159497452" NO="2" P_CHI2="0.5689752035393856" P_Z="0.014057168270294467" STUDIES="5" TAU2="0.0" TOTAL_1="370" TOTAL_2="336" WEIGHT="43.89577203971112" Z="2.455799192202726">
<NAME>Female</NAME>
<DICH_DATA CI_END="2.232025876279861" CI_START="0.8487234475752441" EFFECT_SIZE="1.3763621241495274" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="45" LOG_CI_END="0.3486992251492391" LOG_CI_START="-0.07123379945893424" LOG_EFFECT_SIZE="0.13873271284515248" ORDER="19334" O_E="5.25" SE="0.2466707373568377" STUDY_ID="STD-RANTTAS-I-P_x002f_35-1996" TOTAL_1="146" TOTAL_2="134" VAR="16.43481182795699" WEIGHT="17.272990739081063"/>
<DICH_DATA CI_END="2.3585625624334057" CI_START="0.2680047500374293" EFFECT_SIZE="0.7950509228927437" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.37264740068315855" LOG_CI_START="-0.5718575085952298" LOG_EFFECT_SIZE="-0.09960505395603565" ORDER="19336" O_E="-0.7450980392156854" SE="0.5548068590848296" STUDY_ID="STD-RANTTAS-II-M_x002f_81-1997" TOTAL_1="25" TOTAL_2="26" VAR="3.2487504805843908" WEIGHT="3.414437448517782"/>
<DICH_DATA CI_END="14.04223212953531" CI_START="0.6689343404091435" EFFECT_SIZE="3.0648542032930024" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" LOG_CI_END="1.14743614799954" LOG_CI_START="-0.17461650853625574" LOG_EFFECT_SIZE="0.4864098197316421" ORDER="19338" O_E="1.8571428571428568" SE="0.7765802747153209" STUDY_ID="STD-STIPAS-P_x002f_20-1994" TOTAL_1="35" TOTAL_2="14" VAR="1.658163265306122" WEIGHT="1.742729945760351"/>
<DICH_DATA CI_END="3.2460559994756073" CI_START="1.0452162603845323" EFFECT_SIZE="1.8419637653251135" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="37" LOG_CI_END="0.5113560078048969" LOG_CI_START="0.019206157408469905" LOG_EFFECT_SIZE="0.26528108260668337" ORDER="19335" O_E="7.308900523560212" SE="0.28909125830391086" STUDY_ID="STD-TESS-I-P_x002f_37-1996" TOTAL_1="98" TOTAL_2="93" VAR="11.965478785640398" WEIGHT="12.57572075765773"/>
<DICH_DATA CI_END="2.5446729002339628" CI_START="0.6611227321389519" EFFECT_SIZE="1.2970509242904182" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="30" LOG_CI_END="0.40563196476578983" LOG_CI_START="-0.1797179097384773" LOG_EFFECT_SIZE="0.11295702751365629" ORDER="19337" O_E="2.1999999999999993" SE="0.343837413812416" STUDY_ID="STD-TESS-II-M_x002f_88-1997" TOTAL_1="66" TOTAL_2="69" VAR="8.458507462686567" WEIGHT="8.889893148694192"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.2318354403195975" CI_END="3.685448954690973" CI_START="2.139528758915054" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.808046300913637" ESTIMABLE="YES" EVENTS_1="195" EVENTS_2="79" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.5664904003818996" LOG_CI_START="0.3303181285176242" LOG_EFFECT_SIZE="0.44840426444976195" METHOD="PETO" NO="9" P_CHI2="0.8162245394864243" P_Q="0.6748224278483979" P_Z="9.879655852178347E-14" Q="0.17601278381513374" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="820" TOTAL_2="750" WEIGHT="100.0" Z="7.442501203873526">
<NAME>Infusion site phlebitis</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.3386904445268586" CI_END="3.842950242281403" CI_START="1.847195627887317" DF="2" EFFECT_SIZE="2.6643349800148464" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="42" I2="0.0" ID="CMP-001.09.01" LOG_CI_END="0.5846647613463378" LOG_CI_START="0.2665128919821712" LOG_EFFECT_SIZE="0.4255888266642545" NO="1" P_CHI2="0.5120437836530205" P_Z="1.5742937993004953E-7" STUDIES="3" TAU2="0.0" TOTAL_1="572" TOTAL_2="509" WEIGHT="55.104727097087384" Z="5.243651556419538">
<NAME>Daily dose &lt;= 6 mg/kg/day</NAME>
<DICH_DATA CI_END="3.796038141023083" CI_START="0.9489015534913481" EFFECT_SIZE="1.8979110856753043" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="12" LOG_CI_END="0.5793305673887225" LOG_CI_START="-0.022778842360116996" LOG_EFFECT_SIZE="0.27827586251430275" ORDER="19340" O_E="5.122302158273381" SE="0.3536820477761153" STUDY_ID="STD-RANTTAS-I-P_x002f_35-1996" TOTAL_1="276" TOTAL_2="280" VAR="7.994180817119588" WEIGHT="15.385336021292204"/>
<DICH_DATA CI_END="31.578158535558323" CI_START="0.4917041350236179" EFFECT_SIZE="3.9404455494734836" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.4993868007462672" LOG_CI_START="-0.3082961394617426" LOG_EFFECT_SIZE="0.5955453306422622" ORDER="19339" O_E="1.2162162162162162" SE="1.0618419072530532" STUDY_ID="STD-STIPAS-P_x002f_20-1994" TOTAL_1="84" TOTAL_2="27" VAR="0.8869114815060763" WEIGHT="1.706920505837358"/>
<DICH_DATA CI_END="4.667783962608599" CI_START="1.932197791907668" EFFECT_SIZE="3.003178626997462" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="30" LOG_CI_END="0.6691107475408251" LOG_CI_START="0.28605158146730414" LOG_EFFECT_SIZE="0.4775811645040647" ORDER="19341" O_E="21.71980676328502" SE="0.22501085032503942" STUDY_ID="STD-TESS-I-P_x002f_37-1996" TOTAL_1="212" TOTAL_2="202" VAR="19.75118142503573" WEIGHT="38.01247056995782"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7171322119776051" CI_END="4.494130541493102" CI_START="1.996045587409672" DF="2" EFFECT_SIZE="2.9950775343203304" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="37" I2="0.0" ID="CMP-001.09.02" LOG_CI_END="0.6526456832648447" LOG_CI_START="0.3001704558563509" LOG_EFFECT_SIZE="0.4764080695605979" NO="2" P_CHI2="0.6986775481202033" P_Z="1.169478911938262E-7" STUDIES="3" TAU2="0.0" TOTAL_1="248" TOTAL_2="241" WEIGHT="44.89527290291262" Z="5.298203026341382">
<NAME>Daily dose &gt; 6 mg/kg/day</NAME>
<DICH_DATA CI_END="5.790582044498148" CI_START="0.6629046489567936" EFFECT_SIZE="1.9592355033184645" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="7" LOG_CI_END="0.7627222193421557" LOG_CI_START="-0.17854893526033616" LOG_EFFECT_SIZE="0.2920866420409097" ORDER="19342" O_E="2.1999999999999993" SE="0.5529073355808642" STUDY_ID="STD-M_x002f_57-1996" TOTAL_1="33" TOTAL_2="22" VAR="3.2711111111111113" WEIGHT="6.2954722639812015"/>
<DICH_DATA CI_END="7.447347086673393" CI_START="1.1952136771678363" EFFECT_SIZE="2.983483047816441" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="7" LOG_CI_END="0.8720015947879569" LOG_CI_START="0.07744555425423283" LOG_EFFECT_SIZE="0.47472357452109487" ORDER="19343" O_E="5.018018018018019" SE="0.4667261513253426" STUDY_ID="STD-RANTTAS-II-M_x002f_81-1997" TOTAL_1="53" TOTAL_2="58" VAR="4.590666342017693" WEIGHT="8.835044621748636"/>
<DICH_DATA CI_END="5.39931363192808" CI_START="1.9927295708028172" EFFECT_SIZE="3.280148157687674" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="23" LOG_CI_END="0.7323385552281673" LOG_CI_START="0.2994483654958254" LOG_EFFECT_SIZE="0.5158934603619963" ORDER="19344" O_E="18.371517027863774" SE="0.25428184028977613" STUDY_ID="STD-TESS-II-M_x002f_88-1997" TOTAL_1="162" TOTAL_2="161" VAR="15.465690268285906" WEIGHT="29.764756017182783"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="4.606972349463276" CI_END="13.60134839347515" CI_START="-3.1509358701001524" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="5.225206261687498" ESTIMABLE="YES" I2="34.88131092539534" I2_Q="0.0" ID="CMP-001.10" NO="10" P_CHI2="0.2029448364226395" P_Q="0.7101038773241435" P_Z="0.22145626257194806" Q="0.1381733255908033" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="305" TOTAL_2="246" UNITS="" WEIGHT="100.0" Z="1.2226650316540144">
<NAME>QTc at day 3 (msec)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="24.858787123020008" CI_START="-8.858787123020008" DF="0" EFFECT_SIZE="8.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.10.01" NO="1" P_CHI2="1.0" P_Z="0.3523391608279437" STUDIES="1" TAU2="0.0" TOTAL_1="75" TOTAL_2="26" WEIGHT="24.68513022096873" Z="0.9300616801140106">
<NAME>Daily dose &lt;= 6 mg/kg/day</NAME>
<CONT_DATA CI_END="24.858787123020008" CI_START="-8.858787123020008" EFFECT_SIZE="8.0" ESTIMABLE="YES" MEAN_1="428.0" MEAN_2="420.0" ORDER="1" SD_1="40.0" SD_2="37.0" SE="8.601580057592878" STUDY_ID="STD-STIPAS-P_x002f_20-1994" TOTAL_1="75" TOTAL_2="26" WEIGHT="24.68513022096873"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.468799023872473" CI_END="13.967439364783544" CI_START="-5.335954364420558" DF="2" EFFECT_SIZE="4.315742500181494" ESTIMABLE="YES" I2="55.24524622127928" ID="CMP-001.10.02" NO="2" P_CHI2="0.10705650799878863" P_Z="0.380815288956183" STUDIES="3" TAU2="0.0" TOTAL_1="230" TOTAL_2="220" WEIGHT="75.31486977903127" Z="0.8763951029095377">
<NAME>Daily dose &gt; 6 mg/kg/day</NAME>
<CONT_DATA CI_END="14.315874361236734" CI_START="-26.315874361236734" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="429.0" MEAN_2="435.0" ORDER="4" SD_1="37.0" SD_2="32.0" SE="10.36543248829354" STUDY_ID="STD-M_x002f_57-1996" TOTAL_1="29" TOTAL_2="17" WEIGHT="16.998752063269908"/>
<CONT_DATA CI_END="12.768409368448067" CI_START="-18.76840936844807" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="425.0" MEAN_2="428.0" ORDER="19347" SD_1="39.0" SD_2="41.0" SE="8.045254654078986" STUDY_ID="STD-RANTTAS-II-M_x002f_81-1997" TOTAL_1="50" TOTAL_2="49" WEIGHT="28.217095219366183"/>
<CONT_DATA CI_END="32.26749696519376" CI_START="1.7325030348062391" EFFECT_SIZE="17.0" ESTIMABLE="YES" MEAN_1="426.0" MEAN_2="409.0" ORDER="19348" SD_1="69.0" SD_2="67.0" SE="7.789682405198171" STUDY_ID="STD-TESS-II-M_x002f_88-1997" TOTAL_1="151" TOTAL_2="154" WEIGHT="30.09902249639518"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>